5th anerj congress - interevent | gerenciamento de …sistema.interevent.com.br/_img/_fck/programa...
TRANSCRIPT
1
November 28th - 30th • Windsor Barra Hotel
Rio de Janeiro/Brazil
7th LACTRIMS 2012Latin American Congress of Multiple Sclerosis
5th ANERJ CONGRESS
2 3
MStrength.MScience.
www.genzyme.comwww.msatrium.com
We welcome you to the LACTRIMS Congress 2012. Visit our booth.
The strength of unprecedentedscience. The strength of theMS community. The strengthof our commitment.
LACTRIMS - RIO 2012 PRESIDENT MESSAGE
Dear colleagues, We are announcing the FINAL PROGRAM of the VII LatinAmerican Congress of Multiple Sclerosis, to be held on 28-30 November 2012, in the city of Rio de Janeiro. It will gather together in Brazil the most important Latin-American specialists that investigate, treat and research Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO).
The clinical and laboratorial characteristics of the Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System in the Latin-American population, the prevalence of these diseases in different latitudes of the extensive geographical area, which extends from the frontiers of Mexico to Patagonia, and the environmental and biological factors related to this prevalence, will be the main themes of the Congress. These themes have been arousing a growing interest in the international scientific community and will be a part of the plenary sessions and the round-table discussions with Latin-American specialists selected for their scientific production.
The program is divided into plenary sessions, round-table discussions, oral presentations and sessions for the oral presentation of the posters.
The 19 plenary sessions will be held in the morning, in a single auditorium, with themes about the current state of knowledge and the characteristics of MS and NMO in Latin America. These will be presented by Latin-American specialists who have been identified for their scientific production. Some of these specialists work in the USA, Canada and Europe, where they are the leaders in different fields of knowledge: Sergio Baranzini (USA), Marcelo Kremenchutzky (Canada), Raul Mandler (USA), Victor Rivera (Houston) and Oscar Fernandez (Spain). One of the speakers on NMO will be Professor Jun-ichiKira (Japan), who is the most important researcher on
the optic-spinal form of Asiatic Multiple Sclerosis.
In the afternoon, round-table discussions, courses and oral presentations will be held in four auditoriums.
Three courses of continuous education are programed. Update in multiple sclerosis for all health area staff, Methods of epidemiological research for participants who want to carry out research, and last but not least, a neuro immunology course for specialists in demyelinating diseases.
In five Satellite Symposiums, the current and future treatment of Multiple Sclerosis will be addressed by Latin-American and European specialists.
More than two hundred original studies have been accepted for poster or oral presentation. This will demonstrate the advance of research in poster sessions and oral presentation, disclosing the Latin-American experience in research.
LACTRIMS – RIO 2012 will award prizes for the best works of young researchers and the best posters. Furthermore, it will award prizes for the best publications of studies performed in Latin America between 2010 and 2012.
LACTRIMS – RIO 2012 is designed to strengthen the bonds of friendship between specialists, for the disclosure of research, and the integration of groups for the amplification of Latin-American scientific production in the near future.
Finally a special thanks to all the sponsors that, ethically and friendly made possible the organization of this Congress
Regina Maria Papais AlvarengaLactrims Congress President
4 5
ANERJ PRESIDENT MESSAGE
Dear colleagues,
It is with great satisfaction that we are holding our V
Congressof Neurology of Rio de Janeiro, to be held
this year in partnership with the VII Latin-American
Congress of Multiple Sclerosis (7thLACTRIMS), at
the pleasant and attractive Hotel Windsor Barra
on 28,29 and 30 November. Important names from
Brazilian and world neurology will be present at
both the Congresses, which I am sure will be of
enormous benefit for everyone. Furthermore, we
must highlight this positive opportunity to meet
again with countless colleagues and friends. This
always translates into agreeable and profitable
encounters, interchanges, and exchanges of
experiences.
As has already been communicated by our Secretary
and/or by Interevent, our special partnership,
associates of ANERJ will have a significant discount
when they participate in the two Congresses. The
registration should be made through Interevent
as quickly as possible. Please remember that
this discount is only available to members who
have paid their 2012 membership. After some
important work with Banco Santander, and after
having resolved some outstanding administrative
matters, we are able to offer payment via boleto-
identificado, which facil itates the work and control
of payments. We are sending the boletos for the
membership via email for those who have not yet
made the payment. You can become an associate
or re-register by using the website: www.anerj.
org.br. If you have already paid, please ignore this
message.
On Thursday, 29 November, at the end of the day’s
activities, all the members are invited to our General
Meeting. In this, we will have the opportunity to
present, among other points, some results referring
to the ongoing work of the executive board, which
has been achieved through the collaboration of
everyone, great effort and determination. It is
important to highlight the situation of our new
ANERJ website, with its domain name, hosting
and password. The website offers several social
services, for which we rely on your participation.
It also provides an excellent opportunity to express
all your thoughts. Please send your suggestions on
how to improve ANERJ.
I hope that you all benefit from these two
Congresses that ANERJ has the pleasure to offer
to its associates.
José Mauro Braz de Lima
ANERJ President
Merck Serono é umadivisão da Merck
Merck Serono:science that changes lives
Merck Serono. Over 300 years of tradition,
not only among the professionals in
charge of improving people’s health,
but also among all those who have had
access to its innovating therapies.
Merck Serono’s neurodegenerative
diseases division is working hard
in innovation, and not only for one
biotechnological product showing
our galenic know-how, but rather the
development of new treatment options
and devices, as well as advanced
support services for those stricken with
those diseases. Also considering the
possibilities of scientific development and
improvement for the medical community,
Merck Serono provides several projects
for continued medical education, and
grants incentives for existing educational
projects, publication of scientific papers,
and opportunities for specialization in
major international institutions.
In this important relationship, Merck
Serono is proud of having you as an ally
in the search for a better quality of living
for thousands of patients.
2222/2012 - nov 2012
Anúncio 'Merck Neurologia'.indd 1 11/8/12 11:24 AM
6 7
INDEX
General Information 8
Conference Organization 10
International Speakers 11
National Speakers 13
Map 16
Courses 18
Overview Programme 20
Scientific Program 25
ANERJ Scientific Program 40
Index 48
Oral Presentation 56
E- Poster Presentation ANERJ 58
E- Poster presentation LACTRIMS 64
8 9
GENERAL INFORMATION
Organized by
Conference Secretariat:
Avenida das Américas, n° 3500 | Sala 405 | Bloco Hong Kong 3000
Barra da Tijuca | Rio de Janeiro | Zipcode: 22640-102
Phone: 55 21 3326 3320 | Fax: 21 2437 1483 | Website: www.interevent.com.br
Venue Address
Avenida Lucio Costa, n° 2630 | Barra da Tijuca
Rio de Janeiro | Zipcode: 22620-170
Phone: 55 21 2195 5000 | website: www.windsorhoteis.com.br
Travel Agency
Rua Barão de Ipanema, n° 56 - 3° andar
Copacabana | Rio de Janeiro | Brazil
Phone: 55 21 3265 8882 I Fax: 21 2540 8794 I Website: www.bec-eventos.com.br
Latin-American Committee for Treatment and Research
in Multiple Sclerosis.
Associação de Neurologia do Estado do Rio de Janeiro
Information for SpeakersPlease bring your presentation to the Speakers Room at least 2 hours before your presentation. Speakers
Room: open from 08:00 AM to 07:00 PM
A technician will assist you in transferring the presentation to a central conference server. When the
transfer is complete, the technician performs a quick run of the presentation in order for you to check
whether the presentation runs correctly and that all parts of the presentation are copied.
Please bring your presentation on CD, DVD or memory stick.
HeadsetsPlease collect the headset receivers for simultaneous translation at the headset desks located by the
entrances to the session rooms where translation is provided.
Headsets can be returned right after the session or can be kept during the day. Headsets must be
returned each afternoon before you leave the conference center.
CNAThis congress is certified by CNA - Comissão Nacional de Acreditação.
Participants who are able and registered in CNA and wish to receive the credits should fil l at the form at
the conference secretariat.
Score for all specialties: 10 points
BadgeThe use of the badge will be required in all scientific activities and to access the exhibit area.
There will be 02 categories: prescribers and non-prescribers, so that exhibitors can deliver materials to
the appropriate category.
Prescribers: doctors and residents
Non-prescribers: other health professionals and students.
Lost and FoundFound items should be returned to the conference secretariat. If you lose something, please report to
the conference secretariat for assistance.
10 11
LACTRIMS INTERNATIONAL COMMITTEE
Regina Maria Papais Alvarenga Lactrims 2012 President
Soniza Vieira Alves LeonPresident of the Scientific Committee
Jorge Nogales-Gaete Lactrims’s President
Miguel Angel MaciasLactrims’s Vice President
Claudia CárcamoLactrims’s Secretariat
Violeta DiazLactrims’s Treasurer
Fernando Hammuy Pro Tesoureiro
Fernando Gracia Vocal Titular
Miguel Córdova Vocal Titular
José Cabrera-Gómez
Vocal Titular
Patricio AbadVocal Suplente
Orlando Garcea
Vocal Suplente
ANERJ COMMITTEE
José Mauro Braz de Lima
Maria Clinete Sampaio Lcativa
Antonio Luiz dos Santos Werneck Neto
Regina Maria Papais Alvarenga
Ana Maria Yamada
Marco O Py
Marli Pernes
Solange Dultra
Ana Cristina Cabral de Lima
Ana Claudia C B Leite
COMMITTEE INTERNATIONAL SPEAKERSDenisa Hurtukova
Edgard Rojas Huerto
Edgardo Cristiano
Edgardo Reich
Elizabeth Armas
Fernando Caceres
Fernando Gracia
Fernando Hamuy Díaz De Bedoya
Freda Hernández
Guillermo Gómez
Guillermo Izquierdo
Hans-Peter Hartung
Ibis Soto
Jaime Toro
Jenner Velásquez
Jill Conners
Adriana Carra
Alexander Parajeles
Alina G.quevedo
Ana Lucia Rosso
Andres Villa
Arnoldo Soto
Carlos A. Díaz Manzano
Carlos Cuevas
Carlos Ketzoian
Carlos Oehninger
Cesar Caparo
Christian Naurath
Claudia Cárcamo
Daniel Amitrano
Daniela Pohl
Darwin Vizcarra
12 13
Sergio Baranzini
Silvia Tenembaum
Teresa Corona
Victor Rivera
Violeta Diaz
Vladmiro Sinay
Walter A Rocca
Yara Ganeo
John Richert
Jorge Barahona
Jorge Correale
Jorge Nogales-Gaete
Jose A Cabrera Gomez
Juan Carlos Alcantara
Juan Garcia Bonitto
Juan Pablo Princich
Jun-Ichi Kira
Lilia Nunez Orozco
Liliana Patrucco
Marcelo Kremenchutzky
Mario O. Melcon
Mario Rivera Kindel
Miguel Angel Macias
Miguel Córdova Ruiz
Nancy Richert
Orlando Garcea
Oscar Fernandez
Oscar Gonzales Gamarra
Patricio Abad
Pedro Cabello
Raul Arcega
Raul Mandler
Ricardo Buzó
Rivera Flores
Roberto Rotta Escalante
NATIONAL SPEAKERS
Carmen Antão Paiva
Celmir De Oliveira Vilaça
Charles Peter Tilbery
Cláudia Cristina Ferreira Vasconcelos
Claudio Heitor Gress
Cleonice Bento
Cristiana Caires
Cristiana Goes
Cristiane Afonso
Cristiane Marins
Damácio Ramon Kaimen Maciel
Daniel Amitrano
Daniel Paes De Almeida Dos Santos
Denise Nicaretta
Denise Sisterolli Diniz
Doralina Guimarães Brum Souza
Douglas Goodin
Eduardo Davidovich
Eduardo Prezzi
Eliana Maranhão
Eliasz Engelhardt
Elizabeth Batista
Elizabeth Regina Comini Frota
Elza Dias Tosta da Silva
Abelardo De Queiroz C. Araújo
Adailton Pontes
Adriano Miranda
Alberto Alan Gabbay
Alfredo Damasceno
Amilton Antunes Barreira
Ana Beatriz Calmon Nogueira Da Gama
Ana Claudia C. Leite
Ana Cristina Cabral de Lima
Anderson Kuntz Grzesiuk
André Matta
Andre Muniz
Angelo Maiolino
Antonio Gomes Neto
Antonio Luiz Werneck
Arthur Padão Gosling
Benito Damasceno
Bernardo Liberato
Bruno Castelo Branco
Bruno Coutinho
Camila Pupe
Camila Rodrigues
Carla Quero
Carlos Henrique Melo Reis
14 15
Joseph Brooks
Leila Chimelli
Leonardo de Deus Silva
Leticia Fezer
Lucia Fontenelle
Luiz Claudio Thuler
Luiz Domingos Mendes Melges
Luiz Felipe Vasconcellos
Mônica Koncke Fiuza Parolin
Marcelo Cagy
Marcio Bezerra
Marco Antonio Araújo Leite
Marco Antonio Sales Dantas De Lima
Marco Oliveira Py
Marco Tulio Medina
Marcos Papais Alvarenga
Marcus Tulius T. Silva
Maria Cecília de Vecino
Maria Clinete Sampaio Lacativa
Maria Cristina Del Negro Barroso Freitas
Maria Eugênia Tejada Ocampo
Maria Fernanda Mendes
Maria Lúcia Brito Ferreira
Maria Lúcia Vellutini Pimentel
Maria Lucia Mendonça
Mariana Spitz
Marina Alvarenga
Emerson Gasparetto
Ernani Maciel
Fabíola Rachid Malfetano
Fernanda Erthal
Fernanda Guimarães
Fernanda Moll
Fernanda Pereira
Fernanda Rueda Lopes
Fernando Faria De Andrade Figueira
Fernando Mendonça
Flavio Henrique De Rezende Costa
Gabriel Paiva Da Silva Lima
Giseli Quintanilha
Greice Cardoso De Carvalho Silva
Gustavo Adolfo Rodrigues Valle
Helcio Alvarenga
Helcio Alvarenga Filho
Helio Teive
Heloise Helena de Figueiredo Siqueira
Henry Pereira Da Silva
Isabella Guedes
Jefferson Becker
João Gabriel Dib Farinhas
João Santos Pereira
José Maurício Godoy
José Vicente Martins
Jose Mauro Braz De Lima
Marleide Gomes
Marli Pernes
Marzia P. Sohler
Maurice Vincent
Norma Fleming
Osvaldo Nascimento
Péricles Maranhão-Filho
Palmiro Torrieri Júnior
Patricia Beatriz Christino Marinho
Raphael Breder
Regina Papais Alvarenga
Renata Paes
Ricardo Canuto
Ricardo Turon
Rodrigo Barbosa Thomaz
Rossano Cabral De Lima
Sebastião Eurico
Silvio Pessanha Neto
Solange Vianna Dultra
Soniza Vieira Alves Leon
Soraya Pulier
Suzana Costa Nunes Machado
Tamara Checcacci
Tania Regina D. Saad Salles
Tarso Adoni
Valéria Coelho Santa Rita Pereira
Yara Dadalti Fragoso
Verônica Brandão
Walter Oleschko Arruda
16 17
MAP
18 19
COURSES
COURSE 01ReseaRch Methods aPPlied to MultiPle scleRosis
Date: November 28th
Time: 14:00pm to 16:00pm
Room: SEGÓVIA II
Secretary: Juliane Sauter Dalter | Coordenador: CARLOS KETZOIAN
COURSE 02uPdate - MultiPle scleRosis FoR all
Date: November 29th
Time: 14:00pm to 16:00pm
Room: SEGÓVIA II
TIME PROGRAM Speaker
14:00 - 14:45 Introduction to study design: With examples from multiple sclerosis Walter A. Rocca
14:45 - 15:15 Acuity of the EM diagnosis in neuroepidemiological studies Violeta Diaz
15:15 - 15:45 Capture and recapture application method Mario O. Melcon
15:45 - 16:15 Studies on risk factors in MS Luiz Claudio Thuler
TIME PROGRAM Speaker
14:00 - 14:20 The concept and classification of demyelinating diseases Fabiola Rachid
14:20 - 14:40 Multiple Sclerosis Diagnostic Criteria Liliana Patrucco
14:40 - 15:00 Clinical Isolated Syndrome Roberto Rotta Escalante
15:00 - 15:20 MRI for MS Diagnosis Emerson Gasparetto
15:20 - 15:40 Inflammation and degeneration in MS Goodin
15:40 - 16:00 Treatments Algoritms In MS Carlos Cuevas
COURSE 03NeuRoiMMuNoloGY oF idioPathic iNFlaMMatoRY deMYeliNatiNG diseases
Date: November 30th
Time: 14:00pm to 16:00pm
Room: SEGÓVIA II
TIME PROGRAM Speaker
14:00 - 14:10 Neuroimmunology up to date Andres Villa
14:10 - 14:40 Immunological and pathological features of neuromyelitis optica JUN-ICHI KIRA
14:40 - 15:10 Neuroimmunology of MS Jorge Correale
15:10 - 15:35 Experimental Allergic Encephalitis Alessandro Farias
15:35 - 16:00 TH 17 Cleonice Bento
20 21
QUARTA-FEIRA, 28/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente
08:00 - 10:00 PleNaRY sectioN
09:00 - 10:00 PleNaRY sectioN Movement disorders
10:00 - 10:30 coFFe-BReaK
10:30 - 11:10 PleNaRY sectioN Movement disorders - Part 2
10:30 - 12:00 the state of the art in Ms
11:10 - 12:30 PleNaRY sectioN coGNitioN
12:30 - 13:30involuntary Movements : clinic and botulinum toxin treatment
with eNMG
12:30 - 14:00 NoVaRtis satellite symposium Growing evidence once-daily oral fingolimod in Ms
14:00 - 16:00 Ms treatmentcourse - Research Methods
applied to Mschildren demyelinating diseases epilepsy iidd in latin america
16:00 - 16:30 coFFee BReaK
16:30 - 18:30 Future Ms treatments Neuroepidemiology in MsGenetic and Familiar Ms and
MNo
Rehabilitation and Neurophysiology -
Neuroinfectioniidd in latin america
18:30 - 19:30 opening symposium - alcohology
19:00 - 20:30 simpósio teVa - sharpening the Management of Ms
QUINTA-FEIRA, 29/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente
08:00 - 09:00 Jean Martin charcot section
09:00 - 10:00 What is Ms and What is Not Ms Peripheral Neuropathy and Pain
10:00 - 10:30 coFFee BReaK
10:30 - 11:10 PleNaRY sectioNPeripheral Neuropathy and Pain
- Part 2
10:30 - 12:00 Ms in latin america and canada
11:10 - 12:30 PleNaRY sectioN Neuropediatrics
12:30 - 14:00 Biogen idec symposium : commitment to treatments of demyelinating and Neurodegenerative diseases
14:00 - 16:00 Pit Falls in Ms diagnosis course - update Ms For all Fatigue Motor Neurone iidd in latin america
16:00 - 16:30 coFFee BReaK
16:30 - 18:30 challenges in Msupdate in Methods of
investigationcognition iidd in latin america
16:30 - 18:00 Neurommunology
18:00 - 19:00 aNeRJ General assembly
18:30 - 20:00 simpósio MeRcK
OVERVIEW PROGRAMME
22 23
SEXTA-FEIRA, 30/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente
08:00 - 10:00 PLENARY SECTION
09:00 - 10:00 Neuromyelitis Optica Headache
10:00 - 10:30 COFFEE BREAK
10:30 - 10:50 PLENARY SECTION Headache - Part 2
10:30 - 12:00 Neuromyelitis Optica
10:50 - 12:30 PLENARY SECTION History of Medicine
12:30 - 14:00 Bayer Symposium - Impact of MS on Survival and the Role of Interferon β 1-B
12:50 - 13:50 Biogen Idec Conference
14:00 - 16:00 Hot Topics Course - Neuroimmunology of IIDDAdvances in Symptomatic
TreatmentCerebrovascular Diseases Clinical Trials and Guidelines
16:00 - 16:30 coFFee BReaK
16:30 - 18:30 Helcio Alvarenga Award Research in IIDD LACTRIMS Oral Presentation MS Neurointensive Treatment Latin American Committee
18:30 - 19:30 LACTRIMS AND ANERJ CLOSURE SECTION
24 25
QUANTO ANTES MELHOR11,12
• COPAXONE® Does not interfere with the immunological surveillance2,3, differing from immunosupressant drugs that are used in the MS therapy4,8.
• COPAXONE®, Improvement of spasticity can be noted in the first months of treatment9
• COPAXONE® Increased the Quality of Life by 40% in treatment-naive patients in the first 6 months of therapy 10
Copaxone®:FirstchoiceinMStherapy1
Referências: •1.Ministério da Saúde, 2010: DOU 24/09/2010; Portaria nº 493/2010•2.Weber MS, et al. Neurotherapeutics. 2007;4(4):647-653. 2. COPAXONE® prescribing information. Teva Neuroscience, Inc. •3.Aharoni R et al. PNAS. 2008: 105: 11358-63•4.Mundel T. FTY_AAN May 1, 2009•5.Chun J, et al. Clin Neuropharm. 2010;33(2):91-101.•6.Lopez-Diego RS, et al. Nat Rev Drug Discovery. 2008;7(11):909-920. •7.Kappos L, et al. N Engl J Med. 2010;362(5):387-401.•8.Cohen JA, et al. N Engl J Med. 2010;362(5):402-415.•9.Jongen P.J., at al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health and Quality of Life Outcomes 2010, 8:133.•10. Meca-Lallana JE. Balseiro JJ. Et al. Spasticity improvement in patients with relapsing-remittingmultiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. J Neurol Sci. 15;315(1-2):123-8.2012.•11. Miller JR. J Manag Care Pharm. 2004; 10(3)(Suppl B): S4-S11.•12. Mikol DD et al., Lancet Neurol. 2008 Oct;7(10):903-14.CÓ
D. A
NCO
07.11
.12 no
vem
bro/
2012
Contra-indicações: o produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol.Interações medicamentosas: interações entre o COPAXONE® (acetato de glatirâmer) e outras drogas não foram completamente avaliadas.
COPAXONE® (acetato de glatirâmer) - solução injetável - uso subcutâneo 20mg/mL - USO ADULTO - Indicações: Reduzir a freqüência de recidivas nos pacientes com esclerose múltipla remissiva recidivante (EMRR). Ainda não existem estudos comprovando o benefício do COPAXONE® em outras formas de Esclerose Múltipla. Também é indicado no tratamento de pacientes que tiveram um primeiro episódio clínico bem definido e que apre-sentem alto risco de desenvolver a esclerose múltipla clinicamente definida (EMCD). Contra-indicações: O produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol. Advertências e Precauções: A administração deve ser feita exclusivamente por via subcutânea. Não deve ser administrado por via intravenosa; os pacientes devem ser instruídos sobre técnicas de auto-administração da injeção de COPAXONE® para garantir a segurança da administração. Baseado nos dados atuais, não é necessário nenhuma precaução especial para pacientes envolvidos em atividades que requerem alerta mental, como dirigir veículos ou operar máquinas. Como o acetato de glatirâmer pode modificar a resposta imunológica, deve-se considerar a possibilidade de que ele possa interferir com a função imunológica. Gravidez e lactação: Categoria B de risco na gravidez. Interações medicamentosas: Interações entre o COPAXONE® e outros fármacos não foram completamente avaliadas. Reações Adversas: Reações adversas mais comumente observadas: reações no local de aplicação, vasodilatação, dor no peito, astenia, infecção, dor, náusea, artralgia, ansiedade e hipertonia. Posologia: a dose recomendada para adultos para o tratamento de esclerose múltipla remissiva recidivante é de 20 mg/dia injetada subcutaneamente. VENDA SOB PRESCRIÇÃO MÉDICA. Reg. MS 1.5573.0001. Farm. Resp.: Mônica Riyoko Nekozuka – CRF-SP n° 16.970. Teva Farmacêutica Ltda. A persistirem os sintomas, o médico deve ser consultado. Documentação Científica e informações adicionais estão à disposição da classe médica, mediante solicitação.*CIS: Síndrome Clínica Isolada. Copaxone possui indicação em bula.
LACTRIMS SCIENTIFIC PROGRAM
26 27
November 28th
08:00 - 10:00 | Plenary SessionRooM seGÓVias
Chair: Jorge Nogales-Gaete
Secretary: Suzana Costa Nunes Machado
08:10 - 08:30 - Opening: Latin America
Keynote Speaker: Victor Rivera
08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory
Idiopathic Diseases in Latin America?
Speaker 1: Regina Papais Alvarenga
09:00 - 09:30 - MS Prevalence in Latin America
Speaker 2: Mario O. Melcon
09:30 - 10:00 - The environmental factors influencing MS immunology mechanism in Latin American
Speaker 3: Jorge Correale
10:00 - 10:30 | Coffee Break
10:30 - 12:00 | Plenary Session - The State of the art in Multiple SclerosisRooM seGÓVias
Chair: Soniza Vieira Alves Leon
Secretary: Damácio Ramon Kaimen Maciel
10:30 - 11:00 - Mapping genetic susceptibility and modeling pathogenesis in multiple sclerosis
Speaker 1: Sergio E Baranzini
11:00 - 11:30 - The role of the Blood Brain Barrier in Multple Sclerosis
Speaker 2: Andres Villa
11:30 - 12:00 - Epidemiology of multiple sclerosis: The need to integrate new approaches to its reality
Speaker 3: Oscar Fernandez
12:30 - 14:00 | Novartis Symposium Growing evidence once-daily oral fingolimod in MSRooM seGÓVias
12:30 - 12:40 | Welcome and introduction
Speakers: Soniza Vieira Alves Leon & Nadina Frider
12:40 - 13:10 | Scientific paradigms in MS – Burden of disease and unmet needs
Speaker: Jaume Sastre Garriga
13:10 - 13:40 | Growing evidence for the benefit–risk profile of treatment with fingolimod
Speaker: Heinz Wiendl
13:40 - 13:55 | Q&A (clinical cases)
Speaker: Soniza & Speakers
13:55 - 14:00 | Closing remarks ECTRIMS slides
Speaker: Soniza Vieira Alves Leon
14:00 - 16:00 | Activities - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in Latin AmericaRooM oRieNte
Chair: Regina Papais Alvarenga
Secretary: Erlane Fernandez
14:00-14:15 -The IIDD spectrum in Latin America
Speaker 1: Regina Alvarenga
14:15-14:30 - IIDD in Central America
Speaker 2: Fernando Gracia
14:30 - 14:45 - IDD in Mexico
Speaker 3: Rivera Flores
14:45 - 15:00 - IIDD in Venezuela
Speaker 4: Ibis Soto
15:00 - 15:15 - IIDD in Peru
Speaker 5: Cesar Caparo
15:15 - 16:00 - Oral Presentation
15:15 - 15:30 - A 63 - Geographical Distribution of Patients With Multiple Sclerosis treated with
Immunomodulator at Public Healthy System in Chile, 2008-2012
Authors: Jorge Elías Nogales-Gaete;Casandra Ivonne Araya Salfate; Claudio Alonso Eloiza Concha; Luis Rodrigo
Aracena Conte; María Lorena Acevedo González; Paula Carolina Agurto Merino; Séfora Esperanza Martínez
Espinoza; Sergio Omar Cepeda Zumaeta; Silvia Jazmín Labbé Rojas;Vannia Fernanda Díaz Zamorano.
15:30 - 15:45 - A 62 - Genetic variability in Peruvian patients with relapsing remitting multiple sclerosis,
using STR markers DYS390, DYS391, DYS392 Y chromosome
Authors: Miguel Ernesto Cordova Ruiz
15:45 - 16:00 - A 95 - Research Methods applied to Multiple Sclerosis - Neuromyelits Optica and Multiple
Sclerosis: a view from DNA, RNA and protein profiles
Authors:Giselle Penton-Rol;Marcelo Nazabal-Galvez;Hanlet Camacho-Rodríguez;Seydi Pedroso-Santana;Seydi Pedroso-
Santana;Majel Cervantes- Llanos; Alberto Cintado- Benítez;Mayte Ale-Martínez;Adelaida Villarreal-Barrios;Tamara
Díaz-Argudín;Jesus Benítez-Fuentes;Nancy Pavón-Fuentes;Daymet Grass;Jose Antonio Cabrera-Gómez.
Speaker: Mario O. Melcon
14:00 - 14:30 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesFyngolimod - 1st line therapy x 2nd line therapyRooM seGÓVia i
Chair: Edgardo Cristiano
Secretary: Isabella D´Andrea Meira
14:00 - 14:15 - Fyngolimod 1st line therapy
Speaker 1: Orlando Garcea
14:15 - 14:30 - Fyngolimod 2nd line therapy
Speaker 2: Edgardo Cristiano
14:00 - 16:00 | Course - Research Methods applied to Multiple SclerosisRooM seGÓVia ii
Coordinator: Carlos Ketzoian
Secretary: Juliane Sauter Dalter
14:00 - 14:45 - Introduction to study design: With examples from multiple sclerosis
Speaker: Walter A Rocca
14:45 - 15:15 - Acuity of the MS diagnosis in neuroepidemiological studies
Speaker: Violeta Diaz
15:15 - 15:45 - Capture and recapture application method
28 29
15:45 - 16:15 - Studies on risk factors in MS
Speaker: Luiz Claudio Thuler
14:00 - 16:00 | Round Table - Children Demyelinating diseasesRooM seGÓVia iii
Chair: Silvia Tenembaum
Secretary: Tania Regina D. Saad Salles
14:00 - 14:30 - ADEM and NMO in children
Speaker 1: Freda Hernández
14:30 - 15:00 - MRI in the differential diagnosis of pediatric demyelinating disorders
Speaker 2: Juan Pablo Princich
15:00 - 15:30 - Pediatric MS
Speaker 3: Daniela Pohl
15:30 - 16:00 - Treatment of pediatric demyelinating disorders
Speaker 4: Silvia Tenembaum
14:30 - 15:00 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesNon responders to IFN BETA or Glatiramer Acetate - switch to what?RooM seGÓVia i
14:30 - 14:45 - Switch one immunomodulator to other
Speaker 3: Adriana Carra
14:45 - 15:00 - Switch to Natalizumab
Speaker 4: Rodrigo Barbosa Thomaz
15:00 - 15:30 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesNatalizumab x Fingolimode for severe MSRooM seGÓVia i
15:00 - 15:15 - Natalizumab
Speaker 5: Marcos Papais Alvarenga
15:15 - 15:30 - Fingolimod
Speaker 6: Jefferson Becker
15:30 - 16:00 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesMS treatment Withdrawal - Is it Possible?RooM seGÓVia i
15:30 - 15:45 - YES!
Speaker 7: Charles PeterTilbery
15:45 - 16:00 – NO!
Speaker 8: Fernando Faria de Andrade Figueira
16:00 - 16:30 | Coffee Break
16:30 - 18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in Latin AmericaRooM oRieNte
Chair: Arnoldo Soto
Secretary: Melina Bernardes
16:30 - 16:50 - IIDD in Argentina
Speaker 1: Adriana Carra
16:50 - 17:10 - IIDD in Colombia
Speaker 2: Juan Garcia Bonitto
17:10 - 17:30 - IIDD in Paraguay
Speaker 3: Fernando Hamuy Díaz de Bedoya and Sara Florentin
17:30 - 17:50 - IIDD in Chile
Speaker 4: Claudia Cárcamo
17:50 - 18:10 - IIDD in Uruguay
Speaker 5: Carlos Oehninger
18:10 - 18:30 - IIDD in Bolivia
Speaker 6: Maria Eugênia Tejada Ocampo
16:30 - 18:30 | Round Table - Future Multiple Sclerosis Treatments
RooM seGÓVia i
Chair: Helcio Alvarenga
Secretary: Vanderson Carvalho Neri
16:30 - 17:00 - Autologus STEM CELL transplantation in MS
Speaker 1: Amilton Antunes Barreira
17:00 - 17:30 - Steam Cell Therapy in Multiple Sclerosis
Speaker 2: Oscar Fernandez
17:30 - 18:00 - Teriflunomide: Targeting Activated Lymphocyte Proliferation
Speaker 3: Victor Rivera
18:00 - 18:30 - Alemtuzumab: Targeting Circulating Lymphocytes by Selective Depletion
Speaker 4: Guillermo Izquierdo
16:30 - 18:30 | Round Table - Neuroepidemiology in MS: Latin American Studies
RooM seGÓVia ii
Chair: Walter A Rocca
Secretary: Heloise Helena de Figueiredo Siqueira
16:30 - 16:45 - Neuroepidemiology in MS: Infections e MS
Speaker 1: Tereza Corona
16:45 - 17:00 - Association Between The Prevalence of MS And Environmental Factors In Latin America
And The Caribbean: An Ecological Study (GEEMAL: Grupo Colaborativo Multicéntrico para el Estudio
de la Esclerosis Múltiple en América)
Speaker 2: CARLOS KETZOIAN
17:00 - 17:15 - Epidemiological MS in Chile
Speaker 3: Violeta Diaz
30 31
17:15 - 17:30 - Pregnancy and MS
Speaker 4: Yara Dadalti Fragoso
17:30 - 17:45 - Epidemiological MS in Cuba
Speaker 5: Jose A Cabrera Gomez
17:45 - 18:30 Oral Presentation
17:45 - 17:55 - A 16 Breastfeeding and risk of Postpartum Relapses in women with Multiple Sclerosis
Authors: Nora Fernández Liguori; Berenice Silva; Diana Klajn;Fernando Cáceres;María Laura Saladino;Orlando Garcea.
17:55 - 18:05 - A 50 Epidemiology of Multiple Sclerosis in The Island of Margarita, Venezuela
Authors: Arnoldo Soto; Enrique Ordaz;Evelyn Bracho;Marisol Gallardo;Simon Gomez.
18:05 - 18:15 - A 51 Epstein-Barr Virus and Smoking Habits in Brazilian patients with Multiple Sclerosis
Authors: Cátia Silva;Celso Luis Silva Oliveira; Fabio Siquineli;Francisco Tomaz Menezes Oliveira;Heloisa Helena
Ruocco;Joseph Bruno Bidin Brooks;Marcus Vinicius Magno Gonçalves; Sidney Gomes;Sonia Beatriz Felix
Ribeiro;Yara Dadalti Fragoso.
18:15- 18:25 - A 52 Epstein-Barr Vírus Infection of the Central Nervous System and Multiple Sclerosis
Disease Activity
Authors: Carlos Otávio Brandão;Adriel dos Santos Moraes;Alessandro S Farias;Alfredo Damasceno;Analeda F
Longhini;Benito Pereira Damasceno;Denise Sayuri Tukada;Felipe Von Glehn; Juan Cabanillas; Leonardo de Deus
Silva;Leonilda M B Santos.
16:30 - 18:30 | Round Table - Genetic and Familiar MS and MNO in Latin AmericaRooM seGÓVia iiiChair: Damácio Ramon Kaimen Maciel
Secretary: Eduardo Paradella
16:30 - 16:50 - Genetics Studies in Latinamerica
Speaker 1: Teresa Corona
16:50 - 17:10 - Genetics aspects of MS in Brazil
Speaker 2: Soniza Vieira Alves Leon
17:10 - 17:30 - Ancestry information markers application to studies of neurological autoimmune
diseases in admixed population
Speaker 4: - Doralina Guimarães Brum Souza
17:30 - 17:50 Familial MS
Speaker 5: Carmen Antão Paiva
17:50 - 18:10 - Genetics in Colombia
Speaker 6: Jaime Toro
18:10 - 18:30 - Discusion
18:30 - 20:30 | TEVA SymposiumSharpening the Management of MSRooM seGÓVias18:30 - 18:40 - Welcome and Introduction
Presenter: Soniza Vieira Alves Leon
18:40 - 19:00 - Importance of Non Biologic Complex Drugs in MS Treatment
Speaker: Jill Conners
19:00 - 19:30 - Widening the Glatiramer Acetate Data: The GALA Study
Speaker: Robert Zivadinov
19:30 - 19:55 - MS Therapy: Addressing the CNS Pathology
Speaker: Denisa Hurtukova
19:55 - 20:00 - Discussion
Discussant: Soniza Vieira Alves Leon
November 29th
08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section
Cellebration of Charcot Birthday in November-29 - ANERJ
RooM seGÓVias
Chair: Jose Mauro Braz de Lima
Speaker: Helcio Alvarenga
Secretary: Maria Clinete Sampaio Lacativa
09:00 - 10:00 | Plenary Session - What is Ms And What is Not Ms
RooM seGÓVias
Chair: Charles PeterTilbery
Secretary: Rodrigo Barbosa Thomaz
09:00 - 09:30 - When one bout and one MRI is MS
Speaker 1: Jorge Barahona
09:30 - 10:00 - When one bout and one MRI is not MS
Speaker 2: Soniza Vieira Alves Leon
10:00 - 10:30 | Coffee Break
RooM seGÓVias
10:30 - 12:00 | Plenary Session - MS in Americas
MS in Latin America and Canada
RooM seGÓVias
Chair: Teresa Corona
Secretary: Doralina Guimarães Brum Souza
10:30 - 10:40 - Natural History MS in Spanish countries
Speaker 1: Liliana Patrucco
10:40 - 11:00 - Natural History MS in Brazil
Speaker 2: Cláudia Cristina Ferreira Vasconcelos
11:00 - 11:20 - Natural History of Pediatric MS in Latin America
Speaker 3: Silvia Tenembaum
11:20 - 12:00 - Natural History MS in Canada
Speaker 4: Marcelo Kremenchutzky
12:30 - 14:00 | Biogen Idec Symposium : Commitment to Treatments of Demyelinating
and Neurodegenerative Diseases
RooM seGÓVias
12:30 - 12:40 - Opening remarks
Chair: Regina Papais Alvarenga
12:40 - 13:15 - Tailoring Therapy for the MS Patient: Challenges in Choosing Right Treatment Options
Speaker: Hans-Peter Hartung
32 33
13:15 - 13:50 - Biogen Idec Neurology: Current Status of Clinical Development
Speaker: Rick Munschauer
13:50 - 14:00 - Closing remarks and Q&A
Moderator: Regina Papais Alvarenga
14:00 - 16:00 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD)
in Latin America
RooM oRieNte
Chair: Cláudia Cristina Ferreira Vasconcelos
Secretary: Mônica Koncke Fiuza Parolin
14:00 - 14:20 - IIDD in Rio Grande do Sul
Speaker: Maria Cecília de Vecino
14:20 - 14:40 - IIDD in Santa Catarina
Speaker: Suzana Costa Nunes Machado
14:40 - 15:00 - IIDD in Paraná
Speaker: Mônica Koncke Fiuza Parolin
14:40 - 15:00 - IIDD in Paraná
Speaker: Walter Oleschko Arruda
15:00 - 15:20 - IIDD in São Paulo
Speaker: Alfredo Damasceno
15:00 - 15:20 - IIDD in São Paulo
Speaker: Luiz Domingos Mendes Melges
15:20 - 15:40 - IIDD in São Paulo
Speaker: Yara Dadalti Fragoso / Maria Sheila Rocha
15:40 - 16:00 - IIDD in Rio de Janeiro
Speaker: Elizabeth Batista, Ana Beatriz Calmon e Maria Lucia Pimentel
14:00 - 16:00 | Round Table - Pit Falls in MS Diagnosis
RooM seGÓVia i
Chair: Sebastião Eurico
Secretary: Claudia Rego
14:00 - 14:20 - Eritematosous Systemic Lupus Versus MS
Speaker 1: Denise Sisterolli Diniz
14:20 - 14:40 - Lyme Disease Versus MS
Speaker 2: Maria Lúcia Vellutini Pimentel
14:40 - 15:00 - Myastenia Gravis and IIDD
Speaker 3: Elza Dias Tosta da Silva
15:00 - 15:20 - Behcet Disease vs MS
Speaker 4: Ernani Maciel
15:20 - 15:40 - HAM-TSP Versus Primary Progressive MS
Speaker 5: Abelardo de Queiroz C. Araújo
15:40 - 16:00 - Hereditary Ataxia vs MS
Speaker 6: Helio Teive
14:00 - 16:00 | Course - Update - Multiple Sclerosis For All
RooM seGÓVia ii
Chair: Luiz Domingos Mendes Melges
Secretary: Letícia Fezer
14:00 - 14:20 - The concept and classification of demyelinating diseases
Speaker: 1: Fabiola Rachid
14:20 - 14:40 - Clinical isolated syndrome
Speaker 2: Roberto Rotta Escalante
14:40 - 15:00 - Multiple Sclerosis Diagnostic Criteria
Speaker 3: Liliana Patrucco
15:00 - 15:20 - MRI for MS Diagnosis
Speaker 4: Emerson Gasparetto
15:20 - 15:40 - Inflammation and degeneration in MS
Speaker 5: Douglas Goodin
15:40 - 16:00 - Treatments Algoritms In MS
Speaker 6: Carlos Cuevas
14:00 - 16:00 | Round Table
Fatigue: a MS “Phantom” Symptom
RooM seGÓVia iii
Chair:Maria Fernanda Mendes
Secretary: Debora Sales
14:00 - 14:20 - Fatigue and MS: An Overview
Speaker 1: Regina Papais Alvarenga
14:20 - 14:40 - Fatigue and MRI
Speaker 2: Fernanda Moll / Fernanda Erthal
14:40 - 15:00 - Fatigue and disability
Speaker 3: Helcio Alvarenga Filho
15:00 - 15:20 - Cognition and Mental Fatigue
Speaker 4: Maria Fernanda Mendes
15:20 - 15:40 - Physical Intervention, Fatigue and Immunology
Speaker 5: Cleonice Bento
15:40 - 16:00 - Fatigue Treatment
Speaker 6: Damácio Ramon Kaimen Maciel
16:00 - 16:30 - Coffee Break
16:30-18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in
Latin America
RooM oRieNte
Chair: Solange Camargo
Secretary:Heloise Helene Siqueira
34 35
16:30 - 16:50 - IIDD in Pernambuco
Speaker 1: Maria Lúcia Brito Ferreira
16:50 - 17:10 - IIDD in Mato Grosso
Speaker 2: Anderson Kuntz Grzesiuk
16:50 - 17:10 - IIDD in Mato Grosso
Speaker 2: Heloise Helena de Figueiredo Siqueira
17:10 - 17:30 - IIDD in Goiás
Speaker 3: Denise Sisterolli Diniz
17:30 - 17:50 - IIDD in Brasília
Speaker 4: Patricia Beatriz Christino Marinho
17:50 - 18:10 - IIDD in Minas Gerais
Speaker 5: Antonio Gomes Neto
16:30-18:30 | Round Table - Challenges in MS: Diagnosis and Therapeutic Decisions
RooM seGÓVia i
Chair: Soniza Vieira Alves Leon
16:30 - 17:10 Differential Diagnosis PML in the Setting of MS
Speaker 1: Nancy Richert
17:10 - 17:30 The Management of Clinical Isolated Syndrome With High Risk to MS Conversion
Speaker 2: Darwin Vizcarra
17:30 - 17:50 The Management of Secondary Progressive MS With Active Lesions In MRI
Speaker 3: Vladmiro Sinay
17:50 - 18:10 The Management of “Benign” MS
Speaker 4: Elizabeth Armas
18:10 - 18:30 The Management of “Severe” MS?
Speaker 5: Gutemberg Augusto Cruz dos Santos
16:30-18:30 | Round Table - Update in Methods of Investigation in Multiple Sclerosis
RooM seGÓVia ii
Chair: Mauricio Klajenberg.
Secretary: Adriano Miranda
16:30 - 17:00 - The role of advanced MRI techniques in the MS Diagnosis Criteria for Multiple Sclerosis
Speaker 1: Emerson Gasparetto
17:00 - 17:30 - Spinal Cord MRI
Speaker 2: Fernanda Rueda Lopes
17:30 - 18:00 - Electrophysiological Methods
Speaker 3: Joseph Brooks
18:00 - 18:30 - Cerebral Spinal Fluid In MS
Speaker 4: Carlos Oehninger
16:30-18:30 | Round Table - President and Delegates of Latin American Committee of
Research and Treatment in Cognition and Multiple Sclerosis
RooM seGÓVia iii
Secretary: Thais Conceição Monteiro
Chair: Benito Damasceno
16:30 - 16:50 - Cognition and MS - Overview
Speaker 1: Miguel Angel Macias
16:50 - 17:10 - MS Cognition Studies in Spanish Speaking Latin American Countries
Speaker 2: Fernando Caceres
17:10 - 17:30 - Cognitive Different Pattern In MS According Clinical Types
Speaker 3: Renata Paes
17:30 - 17:50 - Topics on MS and cognition - Experience in Colombia
Speaker 4: Juan Garcia Bonitto
17:50 - 18:10 - Personality and MS
Speaker 5: Edgardo Reich
18:10 - 18:30 - Cognition and MRI In MS
Speaker 6: Alfredo Damasceno
18:30 - 20:00 | Merck Symposium
RooM seGÓVias
18:30 - 18:40 - Opening
Speaker: Soniza Vieira Alves Leon
18:40 - 19:10 - Optimising Multiple Sclerosis Therapy
Speaker: Oscar fernandez
19:10 - 19:40 - “Multiple Sclerosis - Children’s approach”
Speaker: Silvia Tenembaum
36 37
November 30th
08:00 - 10:00 | Plenary Session
RooM seGÓVias
Chair: Jose A Cabrera Gomez
Secretary: Maria Sheila Rocha
08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome
Speaker 1: Raul Mandler
08:30 - 09:00 - The relative frequency of NMO and Multiple Sclerosis in Latin American
Speaker 2: Regina Papais Alvarenga
09:00 - 10:00 - Demyelinating diseases in Asian population
Speaker 3: Jun-Ichi Kira
10:00 - 10:30 | Coffee Break
RooM seGÓVias
10:30 - 12:00 | Plenary Section - Neuromyelits Optica in Latin America
RooM seGÓVias
Chair: Alberto Alan Gabbay
Secretary: Elizabeth Regina Comini Frota
10:30 - 11:00 - NMO - Genetic and Epidemiology in Cuba and Martinique
Speaker 1: Jose A Cabrera Gomez
11:00 - 11:30 - NMO and Potencial Evoked Visual Test
Speaker 3: Silvio Pessanha Neto
11:30 - 12:00 - MRI pattern in NMO
Speaker 4: Emerson Gasparetto
12:30 - 14:00 | Bayer Symposium - Impact of MS on Survival and the Role of Interferon 1-B
RooM seGÓVias
12:30 - 12:40 - Introduction
Speaker: Marcos Papais Alvarenga
12:40 - 13:10 - Impact of MS on Survival
Speaker:Marcos Papais Alvarenga
13:10 - 13:50 - Interferon β 1-b and Survival
Speaker:Douglas Goodin
13:50 - 13:55 - Q&A
13:55 - 14:00 - Close
14:00 - 16:00 | Round Table - Clinical Trials and Guidelines MS treatment in Latin AmericanRooM oRieNte
Chair: Jorge Nogales-Gaete
Secretary: Valéria Coelho Santa Rita Pereira
14:00 - 14:20 - Brazilian Recommendation for MS treatment: Medical societies X Government
Speaker 1: Elza Dias Tosta da Silva
14:20 - 14:40 - MS Guidelines Treatment in Brazil
Speaker 2: Suzana Costa Nunes Machado
14:40 - 15:00 - MS Guidelines in Latin America
Speaker 3: Adriana Carra
15:00 - 15:20 - MS Guidelines from LACTRIMS
Speaker 4: Patricio Abad
15:20 - 15:40 - Addressing Natalizumab Therapy related Risks (Globally and Locally)
Speaker 6: John Richert
15:40 - 16:00 - Discussion
14:00 - 16:00 | Session - Hot TopicsRooM seGÓVia i
Chair: Antonio Gomes Neto
Secretary: Paulo Christo
14:00 - 14:20 - Chronic cerebro-spinal venous insufficiency
Speaker 1: Leonardo de Deus Silva
14:20 - 14:40 - Biological markers in MS - how long we are?
Speaker 2: Elizabeth Regina Comini Frota
14:40 - 15:00 - Identification of responders and non-responders to immunomoulators
Speaker 3: Valéria Coelho Santa Rita Pereira
15:00 - 15:15 - A 74 Inter- And Intragenerational Study Of Ms Familial Cases In A Reference Center In
The City Of Rio De Janeiro.
Authors: Melina da Silva Bernardes;Carmem Lucia Antão Paiva;Cláudia Vasconcelos;Elizabeth Batista;Fernanda
Ferreira Chaves da Costa Pereira; Marcos Papais Alvarenga;Regina Maria Papais Alvarenga;Solange Camargo.
15:15 - 15:30 - A 81 Molecular targets involved in Pathogenesis and Response to Therapy of
Demyelinating Diseases
Authors: Majel Cervantes-Llanos;Carmen Valenzuela-Silva;Giselle Pentón-Rol; Gregorio Martínez-Sánchez;Ileana
Lopategui-Cabezas;José Cabrera-Gómez; Pedro López-Saura;Ruby Alonso-Ramírez.
15:30 - 15:45 - A 124 Research of Locus Xq22.3 as transcription source for Endogenous Retrovirus and
its association with the Multiple Sclerosis Etiology
Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery; Laura Sumita;Luis S Nali;Maria
Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria;Vitor B Cavenaghi;Vitor Serafim.
15:45 - 16:00 - A 41 Disease modifying therapy withdrawal in relapsing-remitting multiple sclerosis:
follow-up of 40 patients.
Authors: Guilherme Sciascia do Olival; Vitor Breseghello Cavenaghi; Vitor Serafim; Rodrigo Barbosa Thomaz;
Charles Peter Tilbery
38 39
14:00 - 16:00 | Course - Neuroimmunology of Idiopathic Inflammatory Demyelinating DiseasesRooM seGÓVia ii
Secretary: Ulisses Cerqueira Linhares
14:00 - 14:10 - Neuroimmunology up to date
Chair: Andres Villa
14:10 - 14:40 - Immunological and pathological features of neuromyelitis optica
Speaker 1: Jun-Ichi Kira
14:40 - 15:10 - Neuroimmunology of MS
Speaker 2: Jorge Correale
15:10 - 15:35 - Experimental Allergic Encephalitis
Speaker 3: Alessandro Faria
15:35 - 16:00 - The TH17 cell biology in multiple sclerosis and neuromyelitis optica
Speaker 4: Cleonice Bento
14:00-16:00 | Round Table - Advances in Symptomatic TreatmentRooM seGÓVia iii
Chair: Orlando Garcea
Secretary: Camila Rodrigues
14:00 - 14:20 - The Neuro rehabilitation is part of symptomatic treatment
Speaker: Fernando Caceres
14:20 - 14:40 - Bladder and sphincter dysfunction
Speaker: Camila Rodrigues
14:40 - 15:00 - Spasticity
Speaker: Elizabeth Armas
15:00 - 15:20 - Sexual Disfunction
Speaker: Fernando Hammuy Díaz de Bedoya
15:20 - 15:40 - Ataxia and trembling
Speaker: Orlando Garcea
15:40 - 16:00 - Debate
16:30 - 18:00 | Activities - President and Delegates of Latin American Committee of Research and Treatment in Multiple SclerosisRooM oRieNte
Coordinator: Jorge Nogales-Gaete
Secretary: Violeta Diaz
16:30 - 16:50 - LACTRIMS - Who are we?
Speaker: Jorge Nogales-Gaete
16:50 - 17:10 - Groups in Latin American with specific targets: How does it / can it really work?
Speaker: Miguel Córdova Ruiz
17:10 - 17:30 - A new LACTRIMS
Speaker: Miguel Angel Macias
16:30 - 18:30 h | AWARDSHelcio Alvarenga AwardsRooM seGÓVia i
Chair: Helcio Alvarenga
Secretary: Heloise Helena de Figueiredo Siqueira
16:30 - 18:30 | Round Table - Research in IIDD Latin American Syndromes of NMO
spectrum
RooM seGÓVia ii
Chair: Jun-Ichi Kira
Secretary: Marina Papais Alvarenga
16:30 - 16:50 - Caracteristicas da Neurite Optica nas Síndromes do Complexo NMO
Speaker 1: Elizabeth Batista
16:50 - 17:10 - Brainstein syndrome and encephaloty in NMO
Speaker 2: Marcos Papais Alvarenga
17:10 - 17:30 - Positivity frequency of Anti Aqp4 with the Elisa Method in NMO patients treated at the
Sarah Network – Brasilia Unity
Speaker 4: Maria Cristina Del Negro Barroso Freitas
17:30 - 17:50 - Positivity frequency of Anti aqp4 with the Indirect Immunofluorescence Method in
Patients With Nmo in São Paulo
Speaker 3: Tarso Adoni
17:50 - 18:10 - A 54 Resting-State Functional Magnetic Resonance Imaging in the assessment of
patients with Neuromyelitis Optica
Authors: Emerson Leandro Gasparetto; Fabiola Malfetano; Fernanda Cristina Rueda Lopes; Fernanda Miraldi;
Isabela Meira; Paulo Roberto Valle Bahia; Romeu Domingues; Soniza Alves-Leon.
18:10 - 18:30 - Transverse Myelitis Post Dengue Infection
Speaker 4: Adriano Miranda
16:30 - 18:00 | LACTRIMS Oral Presentation MS
RooM seGÓVia iii
Chair: Victor Rivera
Secretary: Fabíola Rachid Malfetano
16:30 - 16:40 - A 3 Acute Disseminated Encephalomyelitis: Presentation in the adult population.
Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery;Laura Sumita;Luis S Nali;Maria
Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria; Vitor B Cavenaghi;Vitor Serafim.
16:40 - 16:50 - A 6 Aplication of the Mcdonald 2010 criteria for the diagnosis of Multiple Sclerosis in
an argentinean cohort of patients with clinically isolated syndromes
Authors: Liiana Patrucco;Edgardo Cristiano;Juan Ignacio Rojas.
16:50 - 17:00 - A 21 Clinical analysis of Malignant MS in a brazilian reference center for MS
Authors:Fabrício da Costa Hampshire de Araújo;Cláudia Cristina Ferreira Vasconcelos ;Gutemberg Augusto
Cruz dos Santos;Juliana Calvet Kallenbach Aurenção;Regina Maria Papais Alvarenga;Solange Maria das Graças
Gomes Camargo.
17:00 - 17:10 - A 42 Prognostic factors of Malignant Multiple Scleosis in a cohort of argentinean patients
Authors: Liliana Patrucco;Edgardo Cristiano;Jimena Miguez;Juan Ignacio Rojas;Verónica Fleitas.
17:10 - 17:20 - A 92 Multiple Sclerosis: natural history and prognostic factors in brazilian patients.
Authors: Gutemberg Augusto Cruz dos Santos;Claudia Cristina Ferreira Vasconcelos;Fabrício Hampshire
Araujo;Juliana Calvet Kallembach;Luiz Claudio Santos Thuler;Regina Maria Papais Alvarenga;Solange Maria das
Graças Gomes Camargo.
40 41
17:20 - 17:30 - A 112 Prevalence of Pseudotumoral Demyelinating Lesions in an oncology reference center
Authors: Yasmine Coura Torres; Marco Antônio Sales Dantas Lima; Soniza Vieira Alves Leon.
17:30 - 17:40 - A 11 Brain atrophy as a non response predictor to Interferon? In Relapsing Remitting
Multiple Sclerosis
Authors: Juan Ignacio Rojas;Edgardo Cristiano;Liliana Patucco.
17:40 - 17:50 - A 12 Brain Atrophy evaluation in Multiple Sclerosis Patients: A comparison study with
clinically isolated syndrome and Neuromyelitis Optica
Authors: Fernanda Miraldi Clemente Pessôa;Emerson Leandro Gasparetto;Fernanda Cristina Rueda Lopes;Soniza
Vieira Alves-Leon.
17:40 - 17:50 - A 35 Cytokine profile in Relapsing-Remitting Multiple Sclerosis patients and the
association with the progression and the activity of the disease
Authors: Ana Paula Kallaur;Andréa Name Colado Simão;Damácio Ramon Kaimen-Maciel;Edna Maria Vissoci
Reiche;Elaine Regina Delicato de Almeida;Helena Kaminami Morimoto;Josiane Lopes;Larissa Muliterno
Pelegrino;Renato Marques Andrade;Sayonara Rangel Oliveira;Wildea Lice de Carvalho Jennings Pereira.
18:30-19:30 | Clousure - Hold of the New Lactrims Directors Board and Prize Giving
Ceremony
RooM seGÓVia i
Prizes will be given to the following categories
1. Best Latin American published papers between 2010 and 2012
2. Best posters presented in 7th LACTRIMS-RIO
3. Best posters presented for young researchers in 7th LACTRIMS - RIO
4.Best posters presented in 5th Congress of ANERJ
5. Best works submitted by students in LACTRIMS/ANERJ - HELCIO ALVARENGA AWARD
ANERJ SCIENTIFIC PROGRAM
42 43
12:30 - 13:30 | V Anerj Congress - Symposium
Video-conference: Involuntary Movements: clinic and botulinum toxin treatment
with ENMG
RooM seGÓVia iV
Moderator: Denise Nicaretta
Speakers: Ana Lucia Rosso, Flavio Henrique de Rezende Costa
14:00 - 16:00 | Round Table - V Anerj Congress - Epilepsy thoughout lifeRooM seGÓVia iV
Secretaty: Yara Ganeo
Moderator: Cristiane Marins
14:00 - 14:40 - Neonatal and breastfeeding
Speaker: Lucia Fontenelle
14:40 - 15:20 - Kindergarten and Grammar School
Speaker: Gustavo Adolfo Rodrigues Valle
15:20 - 16:00 - Teenager and Adult
Speaker: Cristiane Afonso
16:00 - 16:30 | Coffee Break
16:30 - 17:30 | Round Table - V Anerj Congress - Rehabilitation and NeurophysiologyRooM seGÓVia iV
Secretaty: Fernanda Guimarães
Moderator: José Vicente Martins
16:30 - 16:50 - Miofascial pain
Speaker: Palmiro Torrieri Júnior
16:50 - 17:10 - Chronic Lumbar pain
Speaker: Verônica Brandão
17:10 - 17:30 - Neuropathic pain
Speaker: Artur Padão Gosling
17:30 - 18:30 | Round Table - V Anerj - NeuroinfectionRooM seGÓVia iV
Secretary: Ricardo Canuto
Moderator: Marzia P. Sohler
17:30 - 18:00 - Neurological manifestations of encephalitis
Speaker: Marcus Tulius T. Silva
18:00 - 18:30 - Neuroimage in encephalitis
Speaker: Isabella Guedes
18:30 - 19:30 | Opening Symposium - V Anerj Congress - Alcoholism Perspective in Public Health
RooM seGÓVia iV
Speaker: Jose Mauro Braz de Lima
November 28th
08:00 - 09:00 | Plenary Session - V Anerj Congress – Lactrims PlenaryRooM seGÓVias
Chair: Jorge Nogales-Gaete
08:10 - 08:30 - Opening
Speaker 1: Victor Rivera
08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory
Idiopathic Diseases in Latin America?
Speaker 2: Regina Papais Alvarenga
09:00 - 10:00 | Round Table - V Anerj Congress - Movement DisordersRooM seGÓVia iV
Secretary: Celmir de Oliveira Vilaça
Moderator: Luiz Felipe Vasconcellos
09:00 - 09:20 - Cognitive alterations in Parkinson’s Disease
Speaker: Raphael Breder
09:20 - 09:40 - Sleep disfunctions in Parkinson’s Disease
Speaker:João Santos Pereira
09:40 - 10:00 - Coréias: Differential diagnostic
Speaker: Mariana Spitz
10:00-10:30 | Coffee Break
10:30 - 11:10 | Round Table - V Anerj Congress - Movement DisordersRooM seGÓVia iV
10:30 - 10:50 - Tiques - Up to date
Speaker: Marco Antonio Araújo Leite
10:50 - 11:10 - Demyelinating Diseases and Movement disfunctions
Speaker: Osvaldo JM Nascimento
11:10 - 12:30 | Round Table - V Anerj Congress - Cognition
RooM seGÓVia iV
Secretary: Denise Nicaretta
Moderator: Tamara Checcacci
11:10 - 11:30 - Alzheimer 2011
Speaker: Ana Cristina Cabral de Lima
11:30 - 11:50 - Dementia with Lewy bodies
Speaker: Luiz Felipe Vasconcellos
11:50 - 12:10 - Mixed Dementia
Speaker: Eliasz Engelhardt
12:10 - 12:30 - Cognitive vascular impairment in sickle cell disease
Speaker: Ana Claudia C. Leite
44 45
14:00 - 14:20 - Genetic contribution in ELA
Speaker: Pedro Cabello
14:20 - 14:40 - Epidemiologic aspects of ELA in Latin America
Speaker: Carlos Ketzoian
14:40 - 15:00 - Epidemiologic aspects of ELA in Brazil / Rio de Janeiro
Speaker: Marli Pernes
15:00 - 15:20 - Conventional Magnetic resonance and advanced image in the diagnosis of ELA. What
are the main data?
Speaker: Isabella Guedes
15:20 - 15:40 - ELA - Syndrome or disease – The Nosological limits
Speaker: Jose Mauro Braz de Lima
15:40 - 16:00 - Debate
16:00 - 16:30 | Coffee Break
16:30 - 18:00 | Conference - V Anerj Congress - NeuroimmunologyHow many MS patients are there in the State of Rio de Janeiro?RooM seGÓVia iV
Secretary: Marina Alvarenga
Moderator: Cláudia Cristina Ferreira Vasconcelos
16:30 - 16:40 - Prevalence study on MS in the city of Rio de Janeiro
Speaker: Maria Clinete Sampaio Lacativa
16:40 - 16:50 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal
da Lagoa
Speaker: Marcos Papais Alvarenga
16:50 - 17:00 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal
dos Servidores do Estado
Speaker: Marcelo Cagy
17:00 - 17:10 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Clementino
Fraga Filho
Speaker: Fabiola Rachid
17:10 - 17:20 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Santa Casa de
Misericórdia
Speaker: Leticia Fezer
17:20 - 17:30 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Pedro
Ernesto
Speaker: José Maurício Godoy
17:30 - 17:40 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Ordem Terceira
da Penitência
Speaker: Fernando Figueira
17:40 - 17:50 - MS Prevalence study in the Sul Fluminense Region
Speaker: Ana Beatriz Calmon Nogueira da Gama
17:50 - 18:00 - Data on MS prevalence studies in patients in the city of Volta Redonda
Speaker: Fernanda Pereira
18:00 - 19:00 | General Assembly Anerj
November 29th
08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section
Cellebration of Charcot Birthday in November-29 - ANERJRooM seGÓVias
Chair: Regina Papais Alvarenga
Speaker: Helcio Alvarenga, Jose Mauro Braz de Lima
09:00 - 10:00 | Round Table - V Anerj Congress - Peripheral Neuropathy and pain - Neuropathies of fine fibers / Neuropathic painRooM seGÓVia iV
Secretary: João Gabriel Dib Farinhas
Moderator: Giseli Quintanilha
09:00 - 09:20 - Pain: Central and peripheral sensitivity – the role of the glial cell
Speaker: André Matta
09:20 - 09:40 - Electroneuromyography in pain?
Speaker:Eduardo Davidovich
09:40 - 10:00 - Automatic evaluation
Speaker: Bruno Coutinho
10:00 - 10:30 | Coffee Break
10:30 - 11:10 | Round Table - V Anerj Congress - Peripheral Neuropathy and Pain – Part 2RooM seGÓVia iV
10:30 - 10:50 - Painful peripheral Neuropathies
Speaker: Camila Pupe
10:50 - 11:10 - New evaluation instruments for fine fiber neuropathies
Speaker: Osvaldo JM Nascimento, Bruno Coutinho
11:10 - 12:40 | Round Table - V Anerj Congress - NeuropediatricsRooM seGÓVia iV
Secretary: Carla Quero
Moderator: Tania Regina D. Saad Salles
11:10 - 11:40 - Perinatal inflammation: Implications for Neurological and Neuropsychiatric diseases in childhood
Speaker:Adailton Pontes
11:40 - 12:10 - Asperger Syndrome X Autistic Specter
Speaker: Rossano Cabral de Lima
12:10 - 12:40 - Learning disorders – It is not always ADHD
Speaker: Solange Vianna Dultra
14:00 - 16:00 | Round Table - V Anerj Congress - Motor NeuroneRooM seGÓVia iV
Secretary: Claudio Heitor Gress
Moderator: Carlos Henrique Melo Reis
46 47
RooM seGÓVia iVNovember 30th
08:00 - 09:00 | PLENARY SESSION - V Anerj Congress - Lactrims Plenary
RooM seGÓVias
Chair: Jose A Cabrera Gomez
Secretary: Maria Sheila Rocha
08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome
Speaker:Raul Mandler
08:30 - 09:00 - Multiple Sclerosis and Neuromyelitis Optica in Caribbean Population
Speaker: José A. Cabrera Gomez
09:00 - 10:00 | Round Table - V Anerj Congress - HeadacheRooM seGÓVia iV
Secretary: Greice Cardoso de Carvalho Silva
Moderator: Eliana Maranhão
09:00 - 09:20 - Migraine aura
Speaker: Maurice Vincent
09:20 - 09:40 - Migraine and cerebellum
Speaker: Cristiana Goes
09:40 - 10:00 - Migraine and vertigo
Speaker: Péricles Maranhão-Filho
10:00 - 10:30 | Coffee Break
10:30 - 10:50 | Round Table - V Anerj Congress - Headache - Part 2RooM seGÓVia iV
10:30 - 10:50 - Migraine and SAF
Speaker: Norma Fleming
10:50 - 12:30 | Round Table - V Congresso da ANERJ - History of MedicineRooM seGÓVia iV
Secretary: Cristiana Goes
Moderator: Maria Clinete Sampaio Lacativa
10:50 - 11:20 - Art in Neurology
Speaker:
10:50 - 11:00 - In Litterature
Speaker: Maria Clinete Sampaio Lacativa
11:00 - 11:10 - In Music
Speaker: Antonio Luiz Werneck
11:10 - 11:20 - In painting and sculpture
Speaker: Péricles Maranhão-Filho
11:20 - 11:50 - Charles David Marsden and the functional anatomy of the base lymph nodes
Speaker: Antonio Luiz Werneck
11:50 - 12:20 - The common origin of teaching practice of mental and neurological diseases in Brazil
Speaker: Marleide Gomes
12:20 - 12:50 - Who’s Who?
Speaker: Péricles Maranhão-Filho
12:50 - 13:50 | imposium Biogen IDEC - Progressive Multifocal
Leucoencephalopathy in MS patients
RooM seGÓVia iV
Chair: Marcelo Cagy
Speaker: Gabriel Paiva da Silva Lima
14:00 - 16:00 | Round Table - V Anerj - Cerebrovascular DiseasesSevere Phase Ischemic CvaRooM seGÓVia iV
Secretary: Eduardo Prezzi
Moderator: Marco Oliveira Py
14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)
Speaker: Henry Pereira da Silva
14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)
Speaker: Soraya Pulier
14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)
Speaker: Christian Naurath
14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)
Speaker: Daniel Paes de Almeida dos Santos
15:30 - 16:00 - Diffusion allied to perfusion in severe ischemia
Speaker: Cristiana Caires
16:00 - 16:30 | Coffee Break
16:30 - 18:00 | Round Table - V Anerj Congress - Neurointensive TreatmentRooM seGÓVia iV
Secretary:Daniel Amitrano
Moderator: Bruno Castelo Branco
16:30 - 16:50 - Vasospasm in HSA – New techniques and treatment
Speaker: Bernardo Liberato
16:50 - 17:10 - The role of the EEG in the Neurointensive care unit
Speaker: Maria Lucia Mendonça
17:10 - 17:30 - Hypothermia. When and what to do?
Speaker: Ricardo Turon
17:30 - 17:50 - Cranioencephalic Trauma
Speaker: Fernando Mendonça
17:50 - 18:00 - Debate
18:00-19:00 | CLOSURE
V Anerj Congress - Closure
RooM seGÓVia iV
48 49
AUTHORS ABSTRACTS
abib, c. a 25
adoni, t. a 83
agostinho, l. a 9; a 10
aguero, F. a 83
albuquerque, l. a 137; a 152
alcántara, J. a 158
ale-Martínez, M. a 95
alfieri, d. a 148
almeida, e. a 148; a 35
almeida, s. a 36; a 40; a 58; a 83
alonso, R. a 3
alonso-Ramírez, R. a 81
alvarenga Filho, h. a 86; a 107; a 130; a 32
alvarenga, h. a 140; a 37;a 72;a 140; a 1;a 38;a 89; a 97;a 49;a 65; a 74; a 171
alvarenga, M. a 1; a 97; a 38
alvarenga, R. a 72; a 139; a 140; a 37; a 86; a 32; a 26; a 109; a 103; a 106; a 111; a 113; a 114; a 133; a 136; a 151; a 66; a 89; a 90; a 97; a 21; a 29; a 30; a 49; a 57; a 65; a 66; a 74; a 88; a 92; a 107; a 1; a 38; a 171; P 1; P 15;
alves, l. a 25
alves-leon, s. a 144; a 54; a 55; a 112; a 10; a 58; a 88 ; a 96; a 134; a 138; a 36; a 40; a 12; a 83; a 9; a 164; P 9; a 171
andrade, h. a 153
andrade, P. a 19
andrade, R. a 148; a 35; a 104; a 115; a 84
andres Villa a 99
apostolos, s. a 101
araújo, F. a 21; a 92; a 30
araújo, N. a 30
arbildi, M. a 158
arelis, a. a 110; a 163; a 27
arias, e. a 125
armas, e. a 127; a 146
arnold, d. a 46
arruda, W. a 137; a 138; a 83
arzuaga, a. a 76
aurenção, J. a 21
Ávalos, J. a 7
aviña, G. a 45
azevedo, l. a 117; a 56; a 70
Bahia, P. a 132; a 4; a 54
Banwell, B. a 129
Baptista, s. a 36; a 40; a 58; a 83; a 96
Barahona, J. P 8
Baranauskas, V. a 165
Baranzini, s. P 4
Barbosa, a. a 56
Barkhof, F. a 161; a 44
Bar-or, a. a 161; a 24; a 46; a 59
Barreira, a. a 155; a 170
Bastos, a. a 117; a 70
Batista, e. a 140; a 37; a 26; a 38; a 89; a 74
Becker, J. a 137
Beckmann, K. a 131
Benedict, R. a 85
INDEX AUTHORS Benítez-Fuentes, J. a 95
Bento, c. a 169; a 97
Bermudez, J. a 101; a 33
Bernardes, M. a 38; a 74
Besada, c. a 14; a 61 Boyko, a. a 129
Bracho, e. a 50
Brandão, c. a 89; a 52
Brito, c. a 49
Brooks, J. a 126;a 138;a 2;a 51;a 83; a 137
Brucki, s. a 153;a 20
Brum, d. a 155
Buzó, R. a 158
cabanillas, J. a 52
cabral, F. a 144
caceres, F. a 85
cáceres, F. a 16;a 48
cal, h. a 31 calabresi, P. a 161
callegaro, d. a 160;a 101;a 128;a 33
calvet, J. a 37
calzadilla, l. a 91
camacho-Rodríguez, h a 95
camargo, s. a 140;a 37;a 89;a 49;a 74; a 136;a 21;a 30;a 92;a 38
camilo, d. a 165
campanella, l. a 140; a 65
carneiro, M. a 156 carolino,F. a 72
carrá, a. a 83; a 143; a 75; a 43
carrasco, J. a 119; a 122
carvalho, M. a 137; a 138
carvalho, s. a 86; a 32
castillo, M. a 77
catarino, a. a 38
cavenaghi, V. a 124; a 101; a 41
ceragioli, h. a 165
cerqueira, d. a 29; a 30
cervantes- llanos, M. a 95; a 76; a 81
christo, P. a 135; a 28; a 47; a 93; a 5
cintado- Benítez, a. a 76; a 95
claudino, R. a 83
clemente, h. a 107
cohen, J. a 90
comini-Frota, e. a 138; a 83; a 137
concha, c. a 119; a 120; a 121; a 63; a 122
conte, l. a 119; a 120; a 121; a 63
conte, R. a 122
cores, e. a 100; a 99
cores, V. a 8 correa, e. a 83; a 138
correale, J. a 160; a 90; a 34; a 98; P 3
correia, F. a 91
cossío, M. a 95
costa, J. a 134
costa, M. a 113
couto, R. a 115; a 84
cristiano, e. a 160; a 11; a 13; a 14; a 15; a 42; a 6; a 61; a 78
cruz, a. a 108
cruz, e. a 116; a 77
cruz, l. a 150
cukierman, e. a 103; a 66
cúneo, J. a 48
curbelo, c. a 143; a 75; a 43
cutter, G. a 131
damasceno, a. a 83; a 52
50 51
damasceno, B. a 17; a 18; a 52
dawson, K. a 24; a 46; a 59
defanti, i. a 53
deslandes, M. a 37
dias, R. a 86; a 32
díaz, e. a 83
díaz-argudín, t. a 95
diniz, d. a 156
domingues, R. a 132; a 4; a 54; a 134
doring, t. a 144; a 55; a 132; a 4
ebers, G. a 131
edan, G. a 44
eizaguirre, B. a 100; a 99
elliff, d. a 83
enríquez, F. a 80
escobar, d. a 83
espinoza, s. a 119; a 120; a 121; a 63; a 122
Fajardo, c. a 19
Falcón-cama, V. a 76
Faria, t. a 124; a 101
Farias, a. a 154; a 165; a 52
Farinhas, J. a 31; a 67
Fazzito, M. a 128
Fernandes, a. a 133
Fernandes, e. a 26; a 38
Fernández, o. a 65; a 159; a 23; P 6
Fernández-Masso, J. a 76
Ferreira, M. a 137;a 138;a 152
Ferrer, o. a 116
Fêzer, l. a 138; a 167; a 36; a 40; a 53; a 58; a 96; a 55
Figueiredo, a. a 9; a 10
Fink, M. a 101; a 124
Finkelsztejn, a. a 17;a 18
Fiore, a. a 83
Fiorentini, l. a 8
Fleitas, V. a 118; a 15; a 42
Florentin, s. a 118; a 24; a 46; a 59
Fragoso, Y. a 126; a 137; a 138; a 40; a 2; a 51; a 83; a 36; a 17; a 18
Franco, c. a 83
Freedman, M. a 44
Freitas, M. a 102; a 142
Frider, N. a 160; a 90; a 34
Friedreich, a. a 117
Gallardo, M. a 105; a 50; a 64 Gama, P. a 137; a 138
Garcea, o. a 3; a 8; a 16; a 23; a 7
García, F. a 122
Garcia, Y. a 150Garrahan, J. P 12
Gasparetto, e. a 55; a 132; a 134; a 144; a 4; a 54; a 12; P 19
Georgeto, s. a 137; a 138
Gerber, M. a 162
Ghezzi, a. a 129
Giacomo, M. a 83
Giunta, d. a 160
Glehn, F. a 165; a 52; a 71 Gold, R. a 24;a 46;a 59
Gomes Neto, a. a 135;a 28;a 47;a 93;a 5
Gomes, B. a 141
Gomes, M. a 17; a 18
Gomes, s. a 126; a 137; a 138; a 147; a 51; a 83
Gómez, J. a 68; a 76; a 95; a 81; P 17
Gomez, s. a 50
Gómez-añón, a. a 158
Gonçalves, M. a 123; a 137; a 138; a 51;
a 83; a 126
González, M. a 119; a 120; a 121; a 63; a 122
Gonzalo, h. a 79
Goodin, d. a 131
Gracia, F. a 160
Grass, d. a 95
Grzesiuk, a. a 141; a 83
Guerreiro, c. a 155
Guerrero, M. a 23
Guiu, B. a 79
Gumieiro, B. a 141
Gutfilen, G. a 55
hartung, h. a 44
hauser, s. a 161; a 162
havrdova, e. a 24; a 59
hernandez, F. a 91
herrmann, J. a 44
hobi, c. a 128
horta, W. a 10; a 9
hotermans, c. a 59
inojosa, J. a 83
islas, M. a 160; a 163; a 27; a 45; a 80; a 110
itagiba,V. a 132; a 4
Jiménez, G. a 122
Jorge, F. a 128
Kaimen-Maciel, d. a 104; a 115; a 73; a 83; a 84; a 148; a 35;a 137; a 138
Kallaur, a. a 104; a 115; a 73; a 84; a 148; a 35
Kallembach, J. a 30; a 92
Kappos, l. a 161; a 162; a 90; a 44
Kawagoe, K. a 115; a 84
Kay, c. a 94
Kerszberg, M. a 125
Kira, J. a 168; P 16
Kirchmeyer, c. a 57; a 29
Klajn, d. a 16
Kosac, V. a 31; a 67
Kremenchutzky, M. a 131; P 13
Krupp, l. a 129
Kuperman, G. a 48; a 145
Kurukulasuriya, N. a 24; a 59; a 46 lacativa, M. a 88
lagumersindez-denis, N a 76
langdon, d. a 131
lanius, V. a 44
lavado, e. a 115; a 84
lehr, l. a 129
léllis, B. a 141
león, a. a 23
leon, R. a 127; a 146; a 82
leppert, d. a 161; a 162
levya, l. a 65
li, d. a 161
liguori, N. a 3; a 8; a 16; a 23; a 7
lima, a. a 109; a 57
lima, M. a 112
lin, K. a 83
linhares, u. a 97; a 38
longhini, a. a 154; a 52 lopategui-cabeza, i. a 81
lopes, F. a 39; a 132; a 134; a 144; a 4; a 12; a 54; a 55
lopes, J. a 104; a 115;a 137; a 138; a 148; a 73; a 83;a 84; a 35
lopes, K. a 32
lópez, e. a 80
lópez-saura, P. a 81
52 53
lorenzoni, P. a 94
lourenço, G. a 36; a 40; a 58; a 83
luetic, G. a 90
luis s Nali a 124
lyrio, M. a 133; a 114
Machado, M. a 152
Machado, s. a 123
Machnicki, G. a 160; a 34; a 48
MacManus, d. a 46
Magalhães, e. a 117; a 56; a 70
Malfetano, F. a 144; a 54; a 138; a 36; a 40; a 58; a 9; a 96; a 10
Mandler, R. P 14
Marcilla, M. a 48 Marin, K. a 26; a 38
Marinho, P. a 102; a 142
Martinez, a. a 83; a 75; a 143
Martínez, a. a 43
Martínez, F. a 158
Martínez-sánchez, G. a 81
Martins, c. a 144
Masterman, d. a 161
Matheus, N. a 26; a 38
Matos, K. a 19
Matta, a. a 67
Matta,a. a 31
Mciiroy, c. a 129
Medeiros, M. a 115; a 84
Meinel, M. a 129
Meira, i. a 54; a 9; a 58; a 36; a 40; a 10; a 96; a 138
Meirelles, a. a 56
Melamud, l. a 100; a 99
Melcon, M. a 48; a 83; P 2
Melo, P. a 128Meltzer, l. a 59
Mendes, M. a 137; a 138
Mendive, M. a 79
Merino, a. a 8
Merino, P. a 122; a 119; a 120; a 121; a 63
Miguez, J. a 15; a 42
Miller, d. a 44; a 46
Miraldi, F. a 54
Moises, F. a 45; a 80
Molina, o. a 116; a 77; a 127; a 146; a 82
Moll, F. a 166
Montalbán, X. a 44
Monteagudo, a. a 68
Monteiro, t. a 30; a 57
Moraes, a. a 165; a 52; a 154
Moraes, l. a 101; a 128; a 33
Moraga, M. a 129
Moral, e. a 79
Morales, N. a 83
Morales, R. a 138; a 137; a 83
Moreira, a. a 152
Moreira, M. a 83
Moreira, s. a 83
Morimoto. h. a 148; a 73; a 35
Muniz, a. a 137; a 138
Nali, l. a 101; a 33
Nascimento, o. a 67; a 31
Naylor, R. a 90
Nazabal-Galvez, M. a 95; a 76
Neri, V. a 140; a 89; a 38
Netto, s. a 26
Nóbrega Junior, a. a 123
Nóbrega, F. a 32
Nogales-Gaete, J. a 120; a 119; a 121; a 63; a 122
Nogueira, l. a 111; a 139; a 151; a 66
Nogueira, s. a 32
Novas, M. a 24; a 59
Novis, s. a 53; a 167
o-connor, P. a 161
oehninger, c. a 158
oger, J. a 131
oliva, t. a 115
olival, G. a 101; a 124; a 33; a 41
oliveira, a. a 101; a 33
oliveira, e. a 154; a 165
oliveira, F. a 126; a 138; a 83; a 137; a 51; a 147
oliveira, s. a 115; a 84; a 104; a 73; a 35; a 148
oliveira,c. a 83; a 2; a 126; a 137; a 138; a 51
ordaz, e. a 50
ortiz, G. a 45; a 80
otranto, K. a 53
Pace, a. a 59
Paes, R. a 109; a 57; a 29; a 107; a 30 Paiva, c. a 74; a 10; a 9
Pamplona, R. a 79
Panis, c a 104
Paradela, e. a 10; a 9
Paredes, M. a 118
Patrucco, l. a 6; a 13; a 14; a 15; a 42; a 61; a 78; a 11; P 10
Paula, R. a 154; a 165
Pavón-Fuentes, N. a 95
Peçanha Neto, s. P 18
Pedroso-santana, s. a 95
Peixoto, e. a 38
Peixoto, M. a 128
Pelegrino, l. a 104; a 35; a 84
Penna e costa, a. a 117; a 56; a 70
Pentón-arias, e. a 76
Pentón-Rol, G. a 76; a 95; a 81
Peralta, s. a 79
Pereira, a. a 49
Pereira, B. a 83
Pereira, d. a 19
Pereira, F. a 49; a 74 Pereira, V. a 144; a 9; a 36; a 40; a 10; a 58; a 88; a 96
Pereira, W. a 115; a 84; a 104; a 73; a 35; a 148
Pérez, a. a 53 Pessôa, F. a 134; a 12
Peterlevitz, a. a 165
Phillips, J. a 24; a 59
Piccolo, a. a 153; a 20
Pimentel, M. a 53; a 167
Pinto, l. a 26
Pinto, s. a 106
Pires, c. a 55 Pleimes, d. a 44
Pohl, d. a 129
Pohl,c. a 44
Polman, c. a 44
Portero-otin, M. a 79
Pradella, F. a 154; a 165; a 60; a 71
Prado, F. a 31
Quero, c. a 56; a 70
54 55
Raghupathi, K. a 24
Rametta, M. a 131
Ramirez, V. a 45
Ramos, J. a 80
Ravelo, M. a 127; a 146; a 82
Reder, a. a 131
Reich, e. a 125
Reiche, e. a 115; a 84; a 104; a 73; a 35; a 148
Resk, M. a 48
Ribeiro, a. a 114
Ribeiro, J. a 83
Ribeiro, s. a 126; a 51; a 83
Rios, G. a 91
Ritter, s. a 90
Rivera, J. a 150; a 160
Rocha, c. a 10; a 9
Rocha, M. a 153; a 20
Rodrigues, B. a 38; a 103; a 66
Rodrigues, d. a 57
Rodrigues, M. a 2
Rodríguez, c. a 83
Rojas, G. a 143; a 75; a 43 Rojas, J. a 160; a 11; a 13; a 14; a 15; a 34; a 42; a 6; a 61; a 78; a 48
Rojas, s. a 119; a 121; a 63; a 122
Romano, c. a 101; a 124; a 33 Romano, M. a 160; a 34
Roque, e. a 108
Rosa, a. a 45
Rosalino, J. a 147
Ruiz, l. a 79
Ruiz, M. a 149; a 62; a 75; a 87
Ruocco, h. a 126; a 137; a 51; a 138
Russo, l. a 83
sá, M. a 117
sá, R. a 56
sabino, P. a 111; a 139; a 151; a 66
safanelli, F. a 137; a 138
safanelli, J. a 83
saladino, M. a 16
sales, d. a 133; a 114
salfate, c. a 122; a 119; a 121; a 63
salgado, P. a 137; a 138
salles, R. a 117 salles, t. a 56; a 70
samira apostolos a 128
sanchez, e. a 45
sanchez, J. a 118 sánchez, M. a 80
sandbrink, R. a 44
santana, d. a 70
santiago, t. a 33
santos, c. a 38
santos, G. a 140; a 37; a 136; a 21; a 92; a 30; a 1 ; a 65; a 57; a 38; a 72
santos, l. a 52; a 154; a 165
santos, l. a 111; a 151; a 66
santos, M. a 154; a 165; a 71
santos, s. a 117
sarmento, e. a 49
sassi, R. a 25
sato, d. a 128
satomi, M. a 137; a 138
sauter, a. a 161
scola, R. a 94
seifer, G. a 48
selmaj, K. a 24; a 59
serafim, V. a 101; a 124; a 41
shearer, K. a 83
silva, B. a 8; a 23; a 7; a 3; a 16
silva, c. a 126; a 51
silva, J. a 67
silva, l. a 52
silva, N. a 17; a 18
simão, a. a 104; a 148; a 73; a 35
simm, R. a 101; a 33; a 128
sinnett, M. a 149; a 75; a 87
siqueira, h. a 141
siquineli, F. a 126; a 51; a 83
soto, a. a 105; a 127; a 146; a 50; a 64; a 82; a 116
soto, i. a 127; a 146; a 82; a 77; a 69
souza, a. a 171 souza, l. a 30
souza, R. a 115; a 84; a 135; a 28; a 47; a 5; a 93
spagnol, G. a 154
steinberg, J. a 75; a 143; a 43
stemper, B. a 44
stephan, M. a 46
sumita, l. a 33; a 101; a 124
sweetser, M. a 24
takemoto, M. a 17; a 18
tenembaum, s. a 129; P 12
thomaz, R. a 101; a 124; a 33; a 41
thuler, l. a 133; a 32; a 151; a 111; a 136; a 66; a 30; a 92; a 97
tilbery, c. a 101; a 124; a 33; a 41
tinbergen, J. a 161; a 162
tomic, d. a 90
torres, d. a 19
torres, Y. a 112
trigueros, J. a 108
tukada, d. a 52
umaki, d. a 102; a 142
Valenzuela-silva, c. a 81
Vanotti, s. a 8; a 100; a 85; a 99
Vasconcelos, c. a 140; a 37; a 86; a 32; a 133; a 97; a 32; a 1; a 13; a 38; a 89; a 30; a 57; a 92; a 21; a 49; a 107; a 65; a 74; P 11
Vasquez, l. a 150
Vazquez, t. a 160; a 157; a 150 Velador, e. a 80
Viglietta, V. a 24; a 46
Villa, a. a 48; a 100; P 5
Villalobos, V. a 116; a 77
Villarreal-Barrios, a. a 95
Viridiana, R. a 110; a 163; a 27
Volpini, W. a 165
Vrech, c. a 43; a 143
Werneck, l. a 94
Wilner, N. a 55; a 39
Yang, M. a 24
Yousry, t. a 46
Ysrraelit, c. a 48
Zalcman, J. a 127; a 146; a 82
Zamalloa, c. a 22
Zamorano, V. a 122; a 119; a 121; a 120; a 63
Zhang, R. a 46
Zumaeta, s. a 119; a 121; a 63; a 122; a 120
56 57
ORAL PRESENTATION
NOVEMBER 29th
ABSTRACT ID TITLE
TIME OF PRESENTATION
SESSION ROOM FIRST AUTHOR
A 62
Genetic variability in Peruvian
patients with relapsing remitting
multiple sclerosis, using STR
markers DYS390, DYS391,
DYS392 Y chromosome
15:25 to 15:40
Idiophatic
Inflammatory
demyelinating
Diseases (IIDD) in
Latin America
OrienteMiguel Ernesto Cordova
Ruiz
A 95
Neuromyelitis Optica and Multiple
Sclerosis: A View from DNA, RNA
and Protein Profiles.
15:35 to 15:45
Idiophatic Inflammatory
demyelinating Diseases
(IIDD) in Latin America
Oriente Giselle Penton-Rol
A 63
Geographical distribution of
patients with multiple sclerosis
treated with immunomodulator
at public healthy system in Chile,
2008-2012
15:15 to 15:25
Idiopathic Inflammatory
demyelinating Diseases
(IIDD) in Latin America
Oriente Jorge Elías Nogales-Gaete
A 16
Breastfeeding and risk of
postpartum relapses in women
with multiple sclerosis
17:45 to 17:55
Neuroepidemiology in
MS: Latin American
Studies
Segóvia II Nora Fernández Liguori
A 50
Epidemiology of Multiple Sclerosis
in the island Oo Margarita,
Venezuela
17:55 to 18:05
Neuroepidemiology in
MS: Latin American
Studies
Segóvia II Arnoldo Soto
A 51
Epstein-Barr virus and smoking
habits in Brazilian patients with
multiple sclerosis
18:05 to 18:15
Neuroepidemiology in
MS: Latin American
Studies
Segóvia II Fabio Siquineli
A 52
Epstein-Barr vírus infection of
the central nervous system and
multiple sclerosis disease activity
18:15 to 18:25
Neuroepidemiology in
MS: Latin American
Studies
Segóvia II Carlos Otávio Brandão
A 41
Disease modifying therapy
withdrawal in relapsing-remitting
multiple sclerosis: follow-up of 40
patients.
16:00 to 16:15 HOT TOPICS Segóvia I
Guilherme Sciascia do
Olival; Vitor Breseghello
Cavenaghi; Vitor Serafim;
Rodrigo Barbosa Thomaz;
Charles Peter Tilbery
NOVEMBER 30th
ABSTRACT ID TITLE
TIME OF PRESENTATION
SESSION ROOM FIRST AUTHOR
A 74Inter- and intragenerational study of MS
familial cases in a reference center in the
city of Rio de Janeiro.
15:15 to 15:30 HOT TOPICS Segóvia IMarcos Papais
Alvarenga
A 81Molecular targets involved in
pathogenesis and response to therapy of
Demyelinating diseases
15:30 to 15:45 HOT TOPICS Segóvia IMajel Cervantes-
Llanos
A 124
Research of locus Xq22.3 as transcription
source for endogenous retrovirus and
its association with the multiple sclerosis
etiology
15:45 to 16:00 HOT TOPICS Segóvia IGuilherme Sciascia
do Olival
A 3Acute Disseminated Encephalomyelitis:
Presentation in the adult population.16:30 to 16:40
LACTRIMS Oral
Presentation MSSegóvia III Ricardo Alonso
A 6
Aplication of the Mcdonald 2010 criteria
for the diagnosis of Multiple Sclerosis in
an argentinean cohort of patients with
clinically isolated syndromes
16:40 to 16:50LACTRIMS Oral
Presentation MSSegóvia III Liiana Patrucco
A 21Clinical Analysis of malignant MS in a
brazilian reference center for MS16:50 to 17:00
LACTRIMS Oral
Presentation MSSegóvia III
Fabrício da Costa
Hampshire de
Araújo
A 42Prognostic factors of malignant multiple
Sscleosis in a cohort of argentinean
patients
17:00 to 17:10LACTRIMS Oral
Presentation MSSegóvia III Liliana Patrucco
A 92Multiple Sclerosis: natural history and
prognostic factors in Brazilian patients.17:10 to 17:20
LACTRIMS Oral
Presentation MSSegóvia III
Gutemberg
Augusto Cruz dos
Santos
A 112Prevalence of pseudotumoral
demyelinating lesions in an oncology
reference center
17:20 to 17:30LACTRIMS Oral
Presentation MSSegóvia III
Yasmine Coura
Torres
A 11Brain Atrophy as a non response predictor
to interferon? In Relapsing Remitting
Multiple Sclerosis
17:30 to 17:40LACTRIMS Oral
Presentation MSSegóvia III Juan Ignacio Rojas
A 12
Brain atrophy evaluation in Multiple
Sclerosis patients: a comparison study
with Clinically Isolated Syndrome and
Neuromyelitis Optica
17:40 to 17:50LACTRIMS Oral
Presentation MSSegóvia III
Fernanda Miraldi
Clemente Pessôa
A 35
Cytokine profile in relapsing-remitting
multiple sclerosis patients and the
association with the progression and the
activity of the disease
17:50 to 18:00LACTRIMS Oral
Presentation MSSegóvia III Ana Paula Kallaur
A 54Resting-state functional Magnetic
Resonance Imaging in the assessment of
patients with neuromyelitis optica
17:50 to 18:10 NMO Segóvia IIEmerson Leandro
Gasparetto
58 59
ABSTRACTS ID
TITLE AUTHORDATE OF
PRESENTATIONTV TIME OF
PRESENTANTION
ANERJ 01Disfunção urinária em mulheres com Esclerose múltipla do Rio de Janeiro
(Brasil)
Camila Rodrigues
de AlmeidaNOVEMBER 28th 1 16:00 às 16:10
ANERJ 02
Depressão induzida por interferon: homogeneidade de magnitude de sintomas depressivos somáticos e
cognitivos em estudo prospectivo em pacientes com hepatite C
Lucas Pereira Jorge de Medeiros
NOVEMBER 28th 1 16:10 às 16:20
ANERJ 03Multiple Sclerosis Lesion Heart x
MitoxantroFrancisco T. M. Oliveira
NOVEMBER 28th 1 16:20 às 16:30
ANERJ 04Neuromyelitis Optica X SPECTRUM
manifestation.Franciso T. M. Oliveira
NOVEMBER 28th 2 16:00 às 16:10
ANERJ 05Injuries of neuroimaging neuritis optical
and neuromyelitis optica.Francisco T. M. Oliveira
NOVEMBER 28th 2 16:10 às 16:20
ANERJ 06Terapia infusional com natalizumabe em pacientes com esclerose: desafio
para o enfermeiro no brasil
Fabiana dos S Carolino
Firmo PereiraNOVEMBER 28th 2 16:20 às 16:30
ANERJ 07Programa de treinamento físico como
fator adjuvante no tratamento da esclerose múltipla
Regina Alvarenga
NOVEMBER 28th 3 16:00 às 16:10
ANERJ 08A Forma Benigna da Esclerose Múltipla:
uma revisão sistemática
Thais Conceição Monteiro
NOVEMBER 28th 3 16:10 às 16:20
ANERJ 09Nível sérico de vitamina D em pacientes
com Esclerose Múltipla atendidos na cidade do Rio de Janeiro
Soniza Vieira Alves Leon
NOVEMBER 28th 3 16:20 às 16:30
ANERJ 10 Espectro Neuromielitis OpticaVeronica Fleitas
NOVEMBER 28th 4 16:00 às 16:10
ANERJ 11
Hemianopsia homônima como Sindrome Clinica Isolada com alto poder de conversão para Esclerose
Múltipla em paciente na quinta década de vida. Relato de caso.
Eduardo Cukierman
NOVEMBER 28th 4 16:10 às 16:20
ANERJ 12
Principais efeitos colaterais do uso de Interferon Beta 1a e Interferon Beta 1B subcutâneo nos pacientes com
Esclerose Múltipla da Santa Casa da Misericórdia do Rio de Janeiro.
Wagner Horta
NOVEMBER 28th 4 16:20 às 16:30
ANERJ 13
Elaboração de um questionário para identificar a presença de comorbidades
em uma série de pacientes com Esclerose Múltipla na cidade do Rio de
Janeiro.
Maristela Cavedagne
NOVEMBER 28th 5 16:00 às 16:10
E-POSTER ANERJ PRESENTATION ANERJ 14
Osteoporose em homem de 50 anos com esclerose múltipla forma surto-
remissão. Relato de caso.
Antonio Carlos
Andrade Alvarenga
Filho
NOVEMBER 28th 5 16:10 às 16:20
ANERJ 15Neuro Behçet:Importância do
Diagnóstico Diferencial
Vanderson Carvalho
NeriNOVEMBER 28th 5 16:20 às 16:30
ANERJ 16Arqueopatologia e dados históricos dos defeitos de formação do Tubo Neural
Renato Manganelli Salomão
NOVEMBER 28th 6 16:00 às 16:10
ANERJ 17 Paralisia periodica HipocalemicaFrancisco
T.M.OliveiraNOVEMBER 28th 6 16:10 às 16:20
ANERJ 18
Prevalência de Achados Orofaringoscópicos em Pacientes
com Roncos Noturnos estudados no Hospital Universitário Gaffrée e Guinle
Felipe de Oliveira
FigueiredoNOVEMBER 28th 6 16:20 às 16:30
ANERJ 19Carcinomatose leptomeníngea: relato
de caso
Isabella Cristina Silva
DefantiNOVEMBER 28th 7 16:00 às 16:10
ANERJ 20Paquimeningite em Granulomatose de
Wegener
Antonio Pereira
Gomes NetoNOVEMBER 28th 7 16:10 às 16:20
ANERJ 21Primary vasculitis of the central nervous
system: a case reportTatiane de
Souza PintoNOVEMBER 28th 7 16:20 às 16:30
ANERJ 22
Comparação esportômica do metabolismo de amônia em atletas de elite durante diferentes protocolos de
treinamento e análise de VO2max
André Nascimento Monteiro
NOVEMBER 28th 8 16:00 às 16:10
ANERJ 23Metabolismo de aminoácidos e de
amônia no desenvolvimento da fadiga central. Uma revisão da literatura atual.
Luis Eduardo Viveiros de
CastroNOVEMBER 28th 8 16:10 às 16:20
ANERJ 24
Concentrações plasmáticas de Alanina; Glutamato; Glutamina e metabolismo de amônia durante sessões repetidas de luta em alta intensidade e curta duração. Uma análise esportômica.
Elizabeth Cataldi
NOVEMBER 28th 8 16:20 às 16:30
ANERJ 25O que a população (des)conhece sobre
epilepsiaYara Dadalti
FragosoNOVEMBER 29th 1 16:00 às 16:10
ANERJ 26O número de casos de Epilepsia de
Etiologia Estrutural/Metabólica pode ser diminuído?
Juliane Sauter
DalbemNOVEMBER 29th 1 16:10 às 16:20
ANERJ 27
Tradução, retrotradução e aplicação do questionário de Limoges (França) numa população de pacientes com
diagnóstico de epilepsia na cidade de Eunápolis - Bahia
Pablo Machado Loureiro
NOVEMBER 29th 1 16:20 às 16:30
60 61
ANERJ 28Epilepsia Mioclônica Juvenil ? Relato
em gêmeas univitelínicas
Cláudia Cecília da Silva Rêgo
NOVEMBER 29th 2 16:00 às 16:10
ANERJ 29Epilepsia mioclônica juvenil ?
paradigma entre focal e generalizada ? Relato de caso.
Ana Carolina Gomes Baltar
NOVEMBER 29th 2 16:10 às 16:20
ANERJ 30
Epilepsia Mioclônica Juvenil: auto-percepção de fatores precipitantes de crises X registros ictais de ativações
investigados por vídeo-EEG
Cláudia Cecília da Silva Rêgo
NOVEMBER 29th 2 16:20 às 16:30
ANERJ 31Mioclonias periorais vs Automatismos
orais ? Relato de CasoSoniza Vieira Alves Leon
NOVEMBER 29th 3 16:00 às 16:10
ANERJ 32Percepção dos estudantes de medicina
acerca da epilepsia
JULIANE SAUTER DALBEM
NOVEMBER 29th 3 16:10 às 16:20
ANERJ 33 Doença de Lafora - Relato de casoShaylla Vilas Bôas Vianna
NOVEMBER 29th 3 16:20 às 16:30
ANERJ 34Padrões Periódicos no
Eletroencefalograma: RevisãoMariana
Silva SouzaNOVEMBER 29th 4 16:00 às 16:10
ANERJ 35Padrão Eletroencefalográfico Periódico:
Aspectos Clínicos, Neuroimagem e Evolução
Mariana Silva Souza
NOVEMBER 29th 4 16:10 às 16:20
ANERJ 36Síndrome do Homem Rígido: relato de
casoClarissa N.
SpitzNOVEMBER 29th 4 16:20 às 16:30
ANERJ 37Estudo clínico, polissonografico e do HLA Classe II em uma série de pacientes brasileiros narcolépticos
Andrea Bacelar
NOVEMBER 29th 5 16:00 às 16:10
ANERJ 38
38. Paraplegia Espástica Hereditária (Síndrome de Staümpell Lorrain):
relato de quatro casos em uma mesma família
Vanderson Carvalho
NeriNOVEMBER 29th 5 16:10 às 16:20
ANERJ 39 Sindrome Pos-Poliojose
h.f.rosalinoNOVEMBER 29th 5 16:20 às 16:30
ANERJ 40The response of the Cutaneous Silent
Period in a group of patients with tunnel carpal syndrome.
Joseph Bruno Bidin
BrooksNOVEMBER 29th 6 16:00 às 16:10
ANERJ 41The response of the Cutaneous Silent
Period in a group of patients with diabetes and polineuropathy.
Joseph Bruno Bidin
BrooksNOVEMBER 29th 6 16:10 às 16:20
ANERJ 42Síndrome do Homem Barril como
apresentação secundária a osteoartrose cervical: um relato de caso
Lucas Oliveira Mourão
NOVEMBER 29th 6 16:20 às 16:30
ANERJ 43Mononeuropatia Multipla e Sindrome
Churg StraussJHF.Rosalino NOVEMBER 29th 7 16:00 às 16:10
ANERJ 44
Estudo Sistemático Anátomo-Cirúrgico dos Ramos do Nervo Musculocutâneo para o Músculo Bíceps Braquial: Bases Anatômicas para a Técnica de Oberlin
Ana Caroline Siquara de
SousaNOVEMBER 29th 7 16:10 às 16:20
ANERJ 45Qual é o sintoma mais precocemente relacionado aos tumores malignos do nervo periférico na neurofibromatose?
Roberto Andre
Torres de Vasconcelos
NOVEMBER 29th 7 16:20 às 16:30
ANERJ 46Polirradiculoneuropatia associada
a quadro reacional em hanseníase: Relato de caso
Louise Mara Giesel
NOVEMBER 29th 8 16:00 às 16:10
ANERJ 47Schwannoma do nervo facial ? Relato
de caso e revisão da literatura
Christiano Assis
Buarque Perlingeiro
NOVEMBER 29th 8 16:10 às 16:20
ANERJ 48
Prevalência e características de dor lombar em uma população de
universitários jovens da área da saúde do município de Santos.
Yara Dadalti Fragoso
NOVEMBER 29th 8 16:20 às 16:30
ANERJ 49
Avaliação do tremor do palato mole e laringe através da
fibronasofaringolaringoscopia em pacientes com doença de Parkinson
Daniella Leitão
MendesNOVEMBER 30th 1 16:00 às 16:10
ANERJ 50
Relação do tempo de doença, distúrbios motores e quantidade de
cuidadores em pacientes com Doença de Huntington ? estudo piloto
Rafael Gonzalez de
OliveiraNOVEMBER 30th 1 16:10 às 16:20
ANERJ 51 Mioclônus Palatal - Relato de caso
Carlos Eduardo Dilen da
Silva
NOVEMBER 30th 1 16:20 às 16:30
ANERJ 52
Estudo intergeracional da Doença de Huntington: dificuldades de
aconselhamento genético preventivo em pacientes com alelos de
penetrância reduzida
Luciana de Andrade
AgostinhoNOVEMBER 30th 2 16:00 às 16:10
ANERJ 53 Hiperfagia na Doença de Alzheimer
Marcela Rodrigues Moreira
Guimarães
NOVEMBER 30th 2 16:10 às 16:20
ANERJ 54Deficiency of vitamin B12 and relationship with Neuro-Image
Sidney Gomes
NOVEMBER 30th 2 16:20 às 16:30
ANERJ 55Efeitos da Vitamina K1 na cognição e
memória de ratos SHR-spVictor Agati Cavargere
NOVEMBER 30th 3 16:00 às 16:10
ANERJ 56Rastreio de síndrome frontal pelo frontal Assessment Battery (FAB)
Rafael Neder NOVEMBER 30th 3 16:10 às 16:20
62 63
ANERJ 57
Estudo comparativo entre o comprometimento cognitivo na Síndrome de Sjögren e Esclerose
Múltipla
Dóra-Neide Rodrigues
NOVEMBER 30th 3 16:20 às 16:30
ANERJ 58Características da cefaleia crônica
recorrente em crianças entre cinco e nove anos de idade
Felipe Moreira
GannoumNOVEMBER 30th 4 16:00 às 16:10
ANERJ 59Demographic and Clinical Profile
of Paediatric Patients with Multiple Sclerosis: A Cohort Study
Mar Mendibe
BilbaoNOVEMBER 30th 4 16:10 às 16:20
ANERJ 60
Singular associação de lesão pseudo tumoral cerebral recorrente em
paciente pediátrico com neuromielite óptica anti-AQP4 negativo
Natalia Matheus
Terrana de Carvalho
NOVEMBER 30th 4 16:20 às 16:30
ANERJ 61 Cefaleia NumularSidney Gomes
NOVEMBER 30th 5 16:00 às 16:10
ANERJ 62Revisão sistemática do uso de
metoclopramida endovenosa no tratamento agudo da enxaqueca
Yara Dadalti Fragoso
NOVEMBER 30th 5 16:10 às 16:20
ANERJ 63Bases genéticas de uma caso raro
de X-ALD forma cerebral infantil em menina
Patricia Reche
NOVEMBER 30th 5 16:20 às 16:30
ANERJ 64 Amnesia Global Transitoria
Jose Henrique Fernandes Rosalino
NOVEMBER 30th 6 16:00 às 16:10
ANERJ 65Dissecçoes Arteriais Espontaneas
BilateralFrancisco
T.M.OliveiraNOVEMBER 30th 6 16:10 às 16:20
ANERJ 66
Suplementação de alfa tocoferol no status neurológicos de ratos
espontaneamente hipertensos com propensão ao acidente vascular encefálico (SHRSP) submetidos a
inibição do óxido nítrico (L-name).
Marcela Rodrigues Moreira
Guimarães
NOVEMBER 30th 6 16:20 às 16:30
ANERJ 67A Acupuntura como terapia
coadjuvante na recuperação de seqüelas de acidente vascular cerebral
Marcos Barros
Caldeira de Andrada
NOVEMBER 30th 7 16:00 às 16:10
ANERJ 68Distúrbio da coagulação na doença
cérebrovascular: relato de caso
Sérgio Augusto P.
NovisNOVEMBER 30th 7 16:10 às 16:20
ANERJ 69Ação da Riboflavina na Lesão
Neurológica após Bloqueio da NOS
Camille Feitoza França
NOVEMBER 30th 7 16:20 às 16:30
ANERJ 70Meningite Criptococcica e surdez
súbita reversível : Um relato de caso
Maria Helena de
Araújo MeloNOVEMBER 30th 8 16:00 às 16:10
ANERJ 71 Mielite MeningocócicaTania Regina
Dias Saad Salles
NOVEMBER 30th 8 16:10 às 16:20
ANERJ 72Paralisia Facial Periférica e Anacusia
Como Manifestação Inicial de Neurossífilis
Carlos Eduardo Dilen da
Silva
NOVEMBER 30th 8 16:20 às 16:30
ANERJ 73Encefalite límbica: uma apresentação
atípica de neurossífilis
Juliana Rezende
DutraNOVEMBER 30th 8 16:20 às 16:30
ANERJ 74What do patients know about
pregnancy in multiple sclerosis?
Cristiane Borges Patroclo
NOVEMBER 30th 1 10:00 às 10:10
ANERJ 75Síndrome de tronco cerebral e
encefalopatia como manifestações do espectro NMO.
Erlane Fernandes
NOVEMBER 30th 1 10:10 às 10:20
ANERJ 76Surdez em pacientes com esclerose
múltipla: 3 relatos de caso
Hugo Fraga Barbosa
LeiteNOVEMBER 30th 1 10:20 às 10:30
ANERJ 77
Teste de Identificação Olfativa em Pacientes Submetidos a Lobectomia
Temporal para Tratamento de Epilepsia Temporal Mesial Refratária
Fernando Andreiuolo Rodrigue
NOVEMBER 30th 2 10:00 às 10:10
ANERJ 78
Perda auditiva por exposição continuada a Níveis de Pressão Sonora
Elevada (NPSE): A proteção auditiva adequada como um fator excludente
do nexo laboral
Jorge Barbosa
Leite NOVEMBER 30th 2 10:10 às 10:20
ANERJ 79
Desenvolvimento e implementação de um sistema de banco de dados
relacional para estudo da prevalência de esclerose múltipla no estado do Rio
de Janeiro.
Carlos Alberto Alves
NOVEMBER 30th 2 10:20 às 10:30
THE ABSTRACTS OF THE 79 PAPERS PRESENTED AS E-POSTERS IN THE
5TH CONGRESS OF THE ANERJ ARE PUBLISHED IN THE SUPPLEMENTT OF
THE REVISTA BRASILEIRA DE NEUROLOGIA.
64 65
E-POSTER LACTRIMS PRESENTATION
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 02
A 116REACTIVATION OF DISEASE ACTIVITY IN PATIENTS
WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB
DISCONTINUATION: A CASE REPORT IN VENEZUELA.
12:30 - 12:40
TREATMENT A 76
INTERFERON BETA AND C-PHYCOCYANIN:
MOLECULAR MECHANISMS ASSOCIATED TO A NEW
COMBINED THERAPY FOR MULTIPLE SCLEROSIS
12:40 - 12:50
Committee: Adriana
Carrá, Juan Bonito
e Charles Tilbery
Secretary: Fabricio da
Costa Araújo
A 82
MONITORING ALGORITHM FOR PATIENTS WITH
MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH
IMMUNOMODULATORS.
12:50 - 13:00
A 90
COMPARISON OF ORAL FINGOLIMOD WITH
INTERFERON BETA-1A IN TREATMENT OF
RELAPSING-REMITTING MULTIPLE SCLEROSIS:
SUBGROUP ANALYSIS OF THE LATIN-AMERICAN
COHORT IN TRANSFORMS STUDY
13:00 - 13:10
A 101
NEW PREDICTIVE MARKERS FOR NATALIZUMAB-
ASSOCIATED PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.
13:10 - 13:20
A 138THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN
PATIENTS WITH MULTIPLE SCLEROSIS13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 03
A 9
ASSOCIATION STUDY IN MULTIPLE SCLEROSIS
(MS): CIITA GENE POLYMORPHISM (RS4774*C)
IN CONJUNCTION WITH THE HLA-DRB1*15:01+
HAPLOTYPE INCREASES THE SUSCEPTIBILITY TO MS.
12:30 - 12:40
GENETICS OF THE IIDD A 10
ASSOCIATION STUDY OF IL7R? (CD127) GENE
POLYMORPHISM (T244I) AND HLA CLASS II WITH
SUSCEPTIBILITY TO MULTIPLE SCLEROSIS IN A
BRAZILIAN SAMPLE
12:40 - 12:50
Committee: Tereza
Corona, Oscar Fernandez
e Doralina Brum
Secretary: André
Figueiredo
A 62
GENETIC VARIABILITY IN PERUVIAN PATIENTS WITH
RELAPSING REMITTING MULTIPLE SCLEROSIS,
USING STR MARKERS DYS390, DYS391, DYS392 Y
CHROMOSOME
12:50 - 13:00
A 65
HIGH FREQUENCY OF HLA ALLELE DRB1*0301
AMONG BRAZILIAN NMO PATIENTS FROM RIO DE
JANEIRO (BRAZIL)
13:00 - 13:10
A 148
TUMOR NECROSIS FACTOR BETA (TNF-?) NCOI
GENETIC POLYMORPHISM IS ASSOCIATED WITH
MULTIPLE SCLEROSIS INDEPENDENTLY OF HLA-
DRB1*
13:10 - 13:20
A 95NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS:
A VIEW FROM DNA, RNA AND PROTEIN PROFILES.13:20 - 13:30
NOVEMBER 28 TH
IIDD - ABSTRACTS OF GENETIC EPIDEMIOLOGY AND PHYSIOLOGY
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 01
A 50EPIDEMIOLOGY OF MULTIPLE SCLEROSIS IN THE
ISLAND OF MARGARITA, VENEZUELA12:30 - 12:40
EPIDEMIOLOGY
OF IDIOPATHIC
INFLAMMATORY
DEMYELINATING
DISEASES
A 68IDIOPATHIC INFLAMMATORY DEMYELINATING
DISEASES OF THE CNS IN CUBA12:40 - 12:50
Committee: C. keitzoan,
Walter Rocca, M.
Melcom, Antonio
Pereira Gomes Netto
Secretary: Heloíse
Siqueira
A 83
MONTH OF BIRTH DOES NOT SEEM TO INTERFERE
WITH THE PREVALENCE OF MULTIPLE SCLEROSIS
FOR SOUTH AMERICAN PATIENTS AT LATITUDES
ZERO TO 40 DEGREES
12:50 - 13:00
A 88 MULTIPLE SCLEROSIS IN THE CITY OF RIO DE JANEIRO 13:00 - 13:10
A 131SURVIVAL OUTCOMES AND CAUSE OF DEATH FROM
THE 21-YEAR LONG-TERM FOLLOW-UP STUDY13:10 - 13:20
A 160SYSTEMATIC REVIEW OF MULTIPLE SCLEROSIS IN
LATIN AMERICA13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 04
A 43
EARLY CLINICAL PREDICTORS OF SUSTAINED
DISEASE-ACTIVITY-FREE STATUS IN PATIENTS WITH
RELAPSING-REMITTING MULTIPLE SCLEROSIS
TREATED WITH INTERFERON BETA AND GLATIRAMER
ACETATE
12:30 - 12:40
TREATMENT A 44
EARLY INITIATION OF INTERFERON BETA-1B AFTER
A FIRST CLINICAL EVENT SUGGESTIVE OF MULTIPLE
SCLEROSIS: CLINICAL OUTCOMES AND USE OF
DISEASE-MODIFYING THERAPY FROM THE BENEFIT
EXTENSION STUDY
12:40 - 12:50
Committee: Edgardo
Cristiano, Rodrigo
Thomaz e Elizabeth
Armas Secretary: Ana
Beatriz Pereira
A 45
EFFECT OF FISH OIL ON CYTOKINES, OXIDATIVE
STRESS MARKERS AND PROGRESSION DISABILITY IN
MULTIPLE SCLEROSIS
12:50 - 13:00
A 46
EFFECTS OF ORAL BG-12 (DIMETHYL FUMARATE)
ON MAGNETIC RESONANCE IMAGING (MRI)
OUTCOMES IN RELAPSING?REMITTING MULTIPLE
SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF
THE PHASE 3 DEFINE AND CONFIRM STUDIES
13:00 - 13:10
A 59
GASTROINTESTINAL TOLERABILITY EVENTS IN
RELAPSING?REMITTING MULTIPLE SCLEROSIS (RRMS)
PATIENTS TREATED WITH ORAL BG-12 (DIMETHYL
FUMARATE) IN DEFINE AND CONFIRM
13:10 - 13:20
A 147TREATMENT OF DISEASE DEVIC WITH
PLASMAPHERESIS AND CORTICOID13:20 - 13:30
66 67
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:00-14:00
TV 05
A 51EPSTEIN-BARR VIRUS AND SMOKING HABITS IN
BRAZILIAN PATIENTS WITH MULTIPLE SCLEROSIS12:00 - 12:10
ENVIRONMENTAL/
GENETIC RISK FACTORA 16
BREASTFEEDING AND RISK OF POSTPARTUM
RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS12:10 - 12:20
Committee: Sérgio
Baranzini, Carmen Paiva,
Andrés Villa, Lucia
Vianna, Elizabeth Frota
Secretary : Denise Costa,
Yasmin Coura Torres
A 52
EPSTEIN-BARR VÍRUS INFECTION OF THE CENTRAL
NERVOUS SYSTEM AND MULTIPLE SCLEROSIS
DISEASE ACTIVITY
12:20 - 12:30
A 36ANALYSIS ON NEONATAL NEWBORN RESULTS
AMONG PACIENTS WITH MULTIPLE SCLEROSIS12:30 - 12:40
A 104
OXIDATIVE STRESS IN RELAPSING-REMITTING
MULTIPLE SCLEROSIS PATIENTS IN CLINICAL
REMISSION: ASSOCIATION WITH EXPANDED
DISABILITY STATUS SCALE
12:40 - 12:50
A 40DETERMINING FACTORS IN DELIVERY ROUTE
AMONG MULTIPLE SCLEROSIS PATIENTS12:50 - 13:00
A 124
RESEARCH OF LOCUS XQ22.3 AS TRANSCRIPTION
SOURCE FOR ENDOGENOUS RETROVIRUS AND
ITS ASSOCIATION WITH THE MULTIPLE SCLEROSIS
ETIOLOGY
13:00 - 13:10
A 126SERUM LEVELS OF VITAMIN D IN BRAZILIAN
PATIENTS WITH MULTIPLE SCLEROSIS13:10 - 13:20
A 154
VITAMIN D3-INDUCED IDO+ TOLEROGENIC
DCS REDUCES THE SEVERITY OF EXPERIMENTAL
AUTOIMMUNE ENCEPHALOMYELITIS13:20 - 13:30
A 137THE PROFILE OF JCV IN BRAZILIAN PATIENTS WITH
MULTIPLE SCLEROSIS USING NATALIZUMAB13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 06
A 3ACUTE DISSEMINATED ENCEPHALOMYELITIS:
PRESENTATION IN THE ADULT POPULATION.12:30 - 12:40
IIDD - FEATURES IN AL A 112PREVALENCE OF PSEUDOTUMORAL DEMYELINATING
LESIONS IN AN ONCOLOGY REFERENCE CENTER12:40 - 12:50
Committee: Fernando
Bedoy, Jorge Nogales
e Vladimiro Sinay
Secretary: Renato
Salomão
A 77UNUSUAL PRESENTATION OF ACUTE HEMORRHAGIC
LEUKOENCEPHALITIS: A CASE REPORT12:50 - 13:00
A 105PARKINSONISM SECONDARY TO PROGRESSIVE
MULTIPLE SCLEROSIS13:00 - 13:10
A 130 FATIGUE AND DISABILITY 13:10 - 13:20
A 147TREATMENT OF DISEASE DEVIC WITH
PLASMAPHERESIS AND CORTICOID13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 07
A 18
BURDEN OF MULTIPLE SCLEROSIS AND
UNMET NEEDS IN BRAZIL: WORK STATUS AND
PRODUCTIVITY LOSS.
12:30 - 12:40
DRUGS AND ECONOMY A 121
RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-
MS.) IN CHILE. DESCRIPTION OF SOCIOECONOMIC
ASPECTS AND IMPACT OF THE COST OF DRUG
THERAPY IN COMPLEX PATIENTS BARROS LUCO
(CABL).
12:40 - 12:50
Committee: Oscar
Gamarra, Miguel
Cordoba e Cezar Caparo
Secretary: Mauricio
Borges
A 17
BURDEN OF MULTIPLE SCLEROSIS AND UNMET
NEEDS IN BRAZIL: PATIENT PREFERENCES FOR MS
TREATMENTS
12:50 - 13:00
A 34
COSTS OF MULTIPLE SCLEROSIS IN LATIN AMERICA
AND THE CARIBBEAN: SYSTEMATIC REVIEW OF THE
LITERATURE
13:00 - 13:10
A 37
DEMOGRAPHIC AND CLINIC CHARACTERISTICS
OF PATIENTS TREATED WITH NATALIZUMAB ? A
BRAZILIAN PRELIMINARY STUDY.
13:10 - 13:20
A 41
DISEASE MODIFYING THERAPY WITHDRAWAL
IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:
FOLLOW-UP OF 40 PATIENTS.
13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 08
A 48ENCOMS: TREATMENT EXPERIENCE, BURDEN, AND
UNMET NEEDS IN12:30 - 12:40
TREATMENT, DRUGS AND
ECONOMYA 63
GEOGRAPHICAL DISTRIBUTION OF PATIENTS
WITH MULTIPLE SCLEROSIS TREATED WITH
IMMUNOMODULATOR AT PUBLIC HEALTHY SYSTEM
IN CHILE, 2008-2012
12:40 - 12:50
Committee: Carlos
Cuevas, Raul Arcega
e Yara Fragoso
Secretary: Camille França
A 145
TREATMENT EXPERIENCE, BURDEN, AND UNMET
NEEDS (ENCOMS) IN MULTIPLE SCLEROSIS STUDY:
THE COSTS OF MS PATIENTS IN ARGENTINA
12:50 - 13:00
A 110
POSITIVE PREDICTORS OF DRUG ADHERENCE IN
A SAMPLE OF MEXICAN PATIENTS WITH MULTIPLE
SCLEROSIS
13:00 - 13:10
A 58
FREQUENCY OF POSITIVITY IN JCV TESTING IN A
MS COHORT OF PATIENTS AND FOLLOW UP AFTER
NATALIZUMAB TREATMENT
13:10 - 13:20
A 41
DISEASE MODIFYING THERAPY WITHDRAWAL
IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:
FOLLOW-UP OF 40 PATIENTS.
13:20 - 13:30
68 69
NOVEMBER 29 TH
ABSTRACTS ON MS, CLINIC, INVESTIGATION, RADIOLOGY AND TREATMENT
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 01
A 136
THE LONG TERM CLINICAL COURSE OF RELAPSING-
REMITTING MS: PROGNOSIS FACTORS IN BRAZILIAN
POPULATION
12:30 - 12:40
NATURAL HISTORY OF
MSA 21
CLINICAL ANALYSIS OF MALIGNANT MS IN A
BRAZILIAN REFERENCE CENTER FOR MS12:40 - 12:50
Committee: Marcelo
Kremenchutzky,
Marco Moreira e
Claudia Vasconcelos
Secretary: Juliana Calvet
A 23
CLINICAL COMPARATIVE STUDY BETWEEN TWO
MULTIPLE SCLEROSIS CENTRES IN SPAIN AND
ARGENTINA
12:50 - 13:00
A 25CLINICAL FEATURES AND MULTIPLE SCLEROSIS
EPIDEMIOLOGICAL IN RIO GRANDE-RS.13:00 - 13:10
A 42PROGNOSTIC FACTORS OF MALIGNANT MULTIPLE
SCLEOSIS IN A COHORT OF ARGENTINEAN PATIENTS13:10 - 13:20
A 74
INTER- AND INTRAGENERATIONAL STUDY OF MS
FAMILIAL CASES IN A REFERENCE CENTER IN THE
CITY OF RIO DE JANEIRO.
13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 02
A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.12:30 - 12:40
NATURAL HISTORY OF
MSA 87
MULTIPLE SCLEROSIS IN PATIENTS OF ETHNIC
SHIPIBO CONIBO IN PERU12:40 - 12:50
Committee: Liliane
Patrucco, Andrés Villa
e Fabíola Malfetano
Secretary: Sandra Garcia
A 92MULTIPLE SCLEROSIS: NATURAL HISTORY AND
PROGNOSTIC FACTORS IN BRAZILIAN PATIENTS.12:50 - 13:00
A 118 UNIT REGISTRATION DEMYELINATING DISEASES 13:00 - 13:10
A 119
RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-
MS) IN CHILE. CLINICAL CHARACTERIZATION OF
PATIENTS TREATED WITH IMMUNOMODULATORS, IN
THE PUBLIC SYSTEM, 2008-2012.
13:10 - 13:20
A 127CLINICALLY ISOLATED SYNDROME: STUDY IN
VENEZUELAN PATIENTS13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 03
A 30
COGNITIVE IMPAIRMENT AND MRI FEATURES
IN BENIGN MULTIPLE SCLEROSIS: PRELIMINARY
RESULTS.
12:30 - 12:40
FATIGUE, COGNITION
AND MSA 78
JUXTACORTICAL LESION VOLUME AND COGNITIVE
PERFORMANCE IN EARLY ONSET RELAPSING
REMITTING MULTIPLE SCLEROSIS PATIENTS
12:40 - 12:50
Committee:
Miguel Macias,
Fernanda Mendes
e Damácio Ramon
Secretary: Simone Batista
A 8
ASSOCIATION BETWEEN CLINICAL PARAMETERS
AND COGNITIVE PERFORMANCE IN RELAPSING-
REMITTING MULTIPLE SCLEROSIS IN BUENOS AIRES
12:50 - 13:00
A 27COGNITION AND PERSONALITY IN A SAMPLE OF
MEXICAN PATIENTS WITH MS.13:00 - 13:10
A 28 COGNITION IN MULTIPLE SCLEROSIS 13:10 - 13:20
A 29COGNITION IN THE INITIAL STAGE OF MULTIPLE
SCLEROSIS ? A PRELIMINARY STUDY13:20 - 13:30
A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 04
A 2A ROLE FOR THE BLINK REFLEX TEST IN THE
DIAGNOSIS AND PROGRESSION OF DISEASE
ASSESSMENT IN MULTIPLE SCLEROSIS.
12:30 - 12:40
COGNITION,
PSYCHOLOGY AND
WALKING
A 111PREDICTIVE FACTORS FOR LOWER WALKING SPEED
IN PERSONS WITH MULTIPLE SCLEROSIS12:40 - 12:50
Committee: Fernando
Cárceres, Miguel Macias
e Alfredo Damasceno
Secretary: Andrea Bacelar
A 155
WALKING DISTANCES COMPARISON BETWEEN
1-MINUTE INTERVALS OF 6-MINUTES WALK TEST IN
MULTIPLE SCLEROSIS PATIENTS
12:50 - 13:00
A 107PERFORMANCE OF PATIENTS WITH MULTIPLE
SCLEROSIS IN D2 TEST13:00 - 13:10
A 109PERSONALITY AND MULTIPLE SCLEROSIS - A
PRELIMINARY STUDY13:10 - 13:20
A 120
RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-MS)
IN CHILE. THE SIX-MINUTE WALKING TEST IN THE
COMPLEX CARE PATIENTS BARROS LUCO (CABL)
13:20 - 13:30
A 125 SELF AWARENESS AND ANOSOGNOSIA IN MULTIPLE SCLEROSIS. 13:30 - 13:40
A 151VALIDITY AND RELIABILITY OF BRAZILIAN VERSION OF THE
MULTIPLE SCLEROSIS WALKING SCALE (MSWS-12)13:40 - 13:50
70 71
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 05
A 103OPTIC NEURITIS FREQUENCY IN PATIENTS WITH
MULTIPLE SCLEROSIS12:30 - 12:40
IIDD: FEATURES IN AL A 6
APLICATION OF THE MCDONALD 2010 CRITERIA
FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS IN
AN ARGENTINEAN COHORT OF PATIENTS WITH
CLINICALLY ISOLATED SYNDROMES
12:40 - 12:50
Committee: Luis Melges,
Isabella D'Andrea Meira
e Carlos Oheringer
Secretary: Wagner Horta
A 7APPLICATION OF 2010 CRITERIA MCDONALD IN A
CLINICALLY ISOLATED SYNDROMES GROUP IN BUENOS AIRES12:50 - 13:00
A 22
CLINICAL AND RADIOLOGICAL CHARACTERISTICS
OF PATIENTS WITH MS IN THE NATIONAL POLICE
HOSPITAL 2000-2010, LIMA – PERU
13:00 - 13:10
A 108PERIMETRIC AND FUNDOSCOPIC FINDINGS IN PATIENTS
WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON13:10 - 13:20
A 64HEMIFACIAL SPASM AS THE FIRST CLINICAL
MANIFESTATION OF MULTIPLE SCLEROSIS13:20 - 13:30
A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 06
A 57
FREQUENCY OF COGNITIVE CHANGES IN THREE
CLINICAL COURSES OF MULTIPLE SCLEROSIS:
RELAPSING/REMITTING, PRIMARY PROGRESSIVE AND
BENIGN, USING A BRIEF NEUROPSYCHOLOGICAL
SCREENING BATTERY
12:30 - 12:40
COGNITION, PAIN,
FATIGUE, DYSPHAGIA
AND SLEEP
A 66COGNITIVE INFLUENCE ON WALKING OF MULTIPLE SCLEROSIS
PATIENTS IN THE ABSENCE OF CLINICAL DISABILITY12:40 - 12:50
Committee: Renata
Paes, Guillermo Gomez
e Jorge Nogales
Secretary: Helcio
Alvarenga Filho
A 67
IDENTIFYING PAIN IN MULTIPLE SCLEROSIS:
PRELIMINARY RESULTS FROM A STUDY IN A
TERTIARY CENTER
12:50 - 13:00
A 84MOOD DISORDERS AND FATIGUE AMONG MULTIPLE
SCLEROSIS PATIENTS13:00 - 13:10
A 85
MULTICENTER STUDY TO ASSESS COGNITIVE AND
NEUROPSYCHIATRIC DISORDERS IN MULTIPLE
SCLEROSIS PATIENTS FROM LATIN AMERICA
-RELACCEM STUDY: LONGITUDINAL ANALYSIS
13:10 - 13:20
A 115SLEEP QUALITY AND DISEASE PROGRESSION
AMONG MULTIPLE SCLEROSIS PATIENTS13:20 - 13:30
A 102
NMO AND NMO COMPLEX: FREQUENCY OF NMO-
IGG ANTIBODY POSITIVITY IN A REHABILITATION
HOSPITAL IN BRASILIA - BRASIL
13:30 - 13:40
A 133
SYMPTOMS OF OROPHARYNGEAL DYSPHAGIA IN
MULTIPLE SCLEROSIS: PREVALENCE AND CLINICAL
FINDINGS IN A BRAZILIAN POPULATION13:40 - 13:50
A 122
RELAPSING REMITTING MULTIPLES SCLEROSIS (RR-
MS) IN CHILE. EVOLUTION OF DYSPHAGIA AND
DYSARTHRIA IN 84 PATIENTS13:50 - 14:00
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 07
A 156EPIDEMIOLOGICAL AND CLINICAL
CHARACTERIZATION OF 100 PATIENTS WITH
MULTIPLE SCLEROSIS OF GOIAS
12:30 - 12:40
PEDIATRIC IIDD A 91MULTIPLE SCLEROSIS: A REALITY AS
DEMYELINATING DISEASE IN PEDIATRICS.12:40 - 12:50
Committee: Silvia
Tenembaum, Tania
Saad e Gustavo Valle
Secretary: Simone Cotrim
A 126SERUM LEVELS OF VITAMIN D IN BRAZILIAN
PATIENTS WITH MULTIPLE SCLEROSIS12:50 - 13:00
A 129
SUBCUTANEOUS INTERFERON BETA-1A IN
PAEDIATRIC PATIENTS WITH MULTIPLE SCLEROSIS:
REGIONAL OUTCOMES IN AN INTERNATIONAL
RETROSPECTIVE STUDY (REPLAY)
13:00 - 13:10
A 53 PEDIATRIC CASE OF MULTIPLE SCLEROSIS 13:10 - 13:20
A 117
RECURRENT MYELITIS AND TUMEFACTIVE
SUPRATENTORIAL LESION IN CHILDHOOD:
NEUROMYELITIS OPTICA (NMO)?
13:20 - 13:30
A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 08
A 72
INFUSION OF NATALIZUMAB IN MULTIPLE
SCLEROSIS:EXPERIMENT REALIZED AT THE LAGOA
HOSPITAL IN RIO DE JANEIRO
12:30 - 12:40
TREATMENT A 76
INTERFERON BETA AND C-PHYCOCYANIN:
MOLECULAR MECHANISMS ASSOCIATED TO A NEW
COMBINED THERAPY FOR MULTIPLE SCLEROSIS
12:40 - 12:50
Committee: Ana Lucia
Brito, Valéria Coelho e
Tharso Adoni Secretary:
Luiz Eduardo Castro
A 82
MONITORING ALGORITHM FOR PATIENTS WITH
MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH
IMMUNOMODULATORS.
12:50 - 13:00
A 90
COMPARISON OF ORAL FINGOLIMOD WITH
INTERFERON BETA-1A IN TREATMENT OF
RELAPSING-REMITTING MULTIPLE SCLEROSIS:
SUBGROUP ANALYSIS OF THE LATIN-AMERICAN
COHORT IN TRANSFORMS STUDY
13:00 - 13:10
A 101
NEW PREDICTIVE MARKERS FOR NATALIZUMAB-
ASSOCIATED PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.
13:10 - 13:20
A 117
RECURRENT MYELITIS AND TUMEFACTIVE
SUPRATENTORIAL LESION IN CHILDHOOD:
NEUROMYELITIS OPTICA (NMO)?
13:20 - 13:30
A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40
72 73
NOVEMBER 30 TH
ABSTRACTS ON NMO, CLINIC, INVESTIGATION AND TREATMENT
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 01
A 1
A LONGITUDINAL STUDY OF BRAINSTEM
INVOLVEMENT IN A COHORT OF NMO BRAZILIAN
PATIENTS FROM RIO DE JANEIRO
12:30 - 12:40
NATURAL HISTORY OF
NMOA 26
CLINICAL PROFILE OR RECURRENT /BILATERAL OPTIC
NEURITIS IN PATIENTS FROM RIO DE JANEIRO.12:40 - 12:50
Committee: Maria
Lucia Pimentel, Tarso
Atoni e Ibis Soto
Secretary: Carlos Alberto
Alves
A 113PREVALENCE OF THYROID DYSFUNCTION AND
AUTOIMMUNITY IN PATIENTS WITH NMO12:50 - 13:00
A 96
NEUROMYELITIS OPTICA FREQUENCY IN A COHORT OF
MULTIPLE SCLEROSIS PATIENTS AND OTHER CENTRAL
NERVOUS SYSTEM DEMYELINATING DISEASES
13:00 - 13:10
A 47 ENCEPHALOPATHY IN NEUROMYELITIS OPTICA 13:10 - 13:20
A 94NEUROMYELITIS OPTICA AFTER THYMECTOMY IN A YOUNG
MYASTHENIA GRAVIS PATIENT USING CYCLOSPORINE13:20 - 13:30
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 02
A 4
ADVANCED MRI TECHNIQUES FOR THE EVALUATION OF
DEMYELINATING DISEASES: WHAT IS FOR RESEARCH AND
WHAT IS FOR CLINICAL PRACTICE
12:30 - 12:40
RADIOLOGY IN MS A 13 BRAIN ATROPHY IN RADIOLOGICALLY ISOLATED SYNDROMES 12:40 - 12:50
Committee: José
Cabrera, Fernanda Moll
e Juan Pablo Princich
Secretary: Nádia Araújo
A 14
BRAIN ATROPHY OVER 1 YEAR OF DISEASE ONSET
PREDICTS LONG TERM CLINICAL STATUS IN RELAPSING
REMITING MULTIPLE SCLEROSIS
12:50 - 13:00
A 15BRAIN VOLUME CHANGES MAY PREDICT CONVERSION IN
RADIOLOGICALLY ISOLATED SYNDROMES13:00 - 13:10
A 61GENDER RELATED DIFFERENCES IN ATROPHY AND LESION LOAD
IN MULTIPLE SCLEROSIS PATIENTS IN BUENOS AIRES, ARGENTINA13:10 - 13:20
A 153
VISUAL EVOKED POTENTIALS MEASURE AND
CORRELATION WITH DISABILITY PROGRESSION (EDSS)
IN RELAPSING?REMITTING (RRMS) AND SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 04
A 11
BRAIN ATROPHY AS A NON RESPONSE PREDICTOR TO
INTERFERON ? IN RELAPSING REMITTING MULTIPLE
SCLEROSIS
12:30 - 12:40
TREATMENT OF MS AND
NMOA 150
USE OF RITUXIMAB IN DEVIC´S DISEASE, TWO YEARS
FOLLOW UP. MEXICAN EXPERIENCE.12:40 - 12:50
Committee: Adriana
Carrá, Suzana Machado
e Patricio Abad
Secretary: Jorge Leite
A 24
CLINICAL EFFICACY AND SAFETY OF ORAL BG-12
(DIMETHYL FUMARATE) IN RELAPSING?REMITTING
MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS
OF THE PHASE 3 DEFINE AND CONFIRM STUDIES
12:50 - 13:00
A 83MONTH OF BIRTH DOES NOT SEEM TO INTERFERE WITH
THE PREVALENCE OF MULTIPLE SCLEROSIS FOR SOUTH
AMERICAN PATIENTS AT LATITUDES ZERO TO 40 DEGREES
13:00 - 13:10
A 89CEREBROSPINAL FLUID FINDINGS IN A SERIES OF CASES OF
NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS: PRIMARY
PROGRESSIVE AND RELAPSING REMITTING FORMS.
13:10 - 13:20
A 79LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS
PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL
PATHOGENIC MECHANISM.
13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 03
A 60
G-CSF ENHANCES FOXP3+ T LYMPHOCYTES AND
MODIFIES THE PROINFLAMMATORY RESPONSE IN
EXPERIMENTAL AUTOIMMUNE NEURITIS
12:30 - 12:40
IIDD IMUNOLOGY
BIOMARKERSA 81
MOLECULAR TARGETS INVOLVED IN PATHOGENESIS AND
RESPONSE TO THERAPY OF DEMYELINATING DISEASES12:40 - 12:50
Committee: Jorge
Correale, Soniza Leon
e Elizabeth Frota
Secretary: Ulisses
Linhares
A 70IMMUNOLOGIC MARKERS VS. THERAPEUTIC HANDLING
OF MULTIPLE SCLEROSIS DURING CHILDHOOD12:50 - 13:00
A 71
IN VIVO ADMINISTRATION OF TLR AGONIST REDUCES
THE SEVERITY OF EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS. THE ROLE OF PLASMACYTOID
DENDRITIC CELLS AND B LYMPHOCYTES
13:00 - 13:10
A 73INSULIN RESISTANCE IS ASSOCIATED WITH DISABILITY IN
MULTIPLE SCLEROSIS PATIENTS13:10 - 13:20
A 79
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS
PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL
PATHOGENIC MECHANISM.
13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
74 75
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 05
A 32
COMPARISON OF FATIGUE AND FUNCTIONAL
STATUS AMONG MULTIPLE SCLEROSIS SUBTYPES
AND NEUROMYELITIS OPTICA
12:30 - 12:40
FATIGUE AND
COGNITIONA 99
NEUROMYELITIS OPTICA: SEARCHING FOR A
COGNITIVE PATTERN12:40 - 12:50
Committee: Fernando
Gracia, Elias Engelhart,
Patricio Abad and Maria
Fernanda Mendes
Secretary: Mariana
Deslandes
A 100NEUROMYELITIS OPTICA: THE NEED TO
UNDERSTAND PATIENTS´ QUALITY OF LIFE12:50 - 13:00
A 139THE RELATIONSHIP BETWEEN FATIGUE AND GAIT IN
PATIENTS WITH MULTIPLE SCLEROSIS13:00 - 13:10
A 114
PROFILE OF THE ORAL AND PHARYNGEAL PHASES
OF SWALLOWING IN PATIENTS WITH MULTIPLE
SCLEROSIS: PRELIMINARY ANALYSIS
13:10 - 13:20
A 79
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS
REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A
POTENTIAL PATHOGENIC MECHANISM.
13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 06
A 93NEUROMYELITIS OPTICA AND ANTIBODY ANTIAQUAPORIN
4: THE EXPERIENCE OF CAPPEM-BH12:30 - 12:40
ANTI AQP4 IN
SYNDROMES OF NMO
COMPLEX
A 102
NMO AND NMO COMPLEX: FREQUENCY OF NMO-
IGG ANTIBODY POSITIVITY IN A REHABILITATION
HOSPITAL IN BRASILIA - BRASIL
12:40 - 12:50
Committee: Cleonice
Bento. Maria Cristina
del Negro Freitas e
Patricia Beatriz Marinho
Secretary: Luciana
Agostinho
A 152
VALUE OF AQUAPORIN-4 ANTIBODY NMO-IGG AT
THE DIAGNOSIS OF CIS, MS AND NMO SPECTRUM
IN PERNAMBUCO, BRAZIL
12:50 - 13:00
A 5ANTI-AQUAPORIN 4 ANTIBODY POSITIVE AND
PROGRESSIVE DISEASE13:00 - 13:10
A 97
FREQUENCY OF ANTI-AQP4 ANTIBODY IN PATIENTS
WITH NEUROMYELITIS OPTICA AND OPTIC SPINAL
MULTIPLE SCLEROSIS
13:10 - 13:20
A 79
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS
REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A
POTENTIAL PATHOGENIC MECHANISM.
13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 07
A 12
BRAIN ATROPHY EVALUATION IN MULTIPLE
SCLEROSIS PATIENTS: A COMPARISON STUDY
WITH CLINICALLY ISOLATED SYNDROME AND
NEUROMYELITIS OPTICA
12:30 - 12:40
RESONANCE AND NMO A 54
RESTING-STATE FUNCTIONAL MAGNETIC
RESONANCE IMAGING IN THE ASSESSMENT OF
PATIENTS WITH NEUROMYELITIS OPTICA
12:40 - 12:50
Committee: José
Cabrera, J Rivera Flores
and Maria Sheila Rocha
Secretary: Marcela
Guimarães
A 55
EVALUATION OF MICROSTRUCTURAL BRAIN
WHITE MATTER DAMAGE IN PATIENTS WITH
NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS
12:50 - 13:00
A 132
SWI PHASE VALUES OF THE WHOLE GRAY AND
WHITE MATTER IN PATIENTS WITH MULTIPLE
SCLEROSIS AND NEUROMYELITIS OPTICA: A
COMPARATIVE STUDY WITH CONTROLS
13:00 - 13:10
A 134
THE CERVICAL SPINAL CORD IN NEUROMYELITIS OPTICA
PATIENTS: A COMPARATIVE STUDY WITH MULTIPLE
SCLEROSIS USING DIFFUSION TENSOR IMAGING
13:10 - 13:20
A 144TRACT BASED SPATIAL STATISTICS (TBSS) IN THE
EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION
12:30-14:00
TV 08
A 138THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN
PATIENTS WITH MULTIPLE SCLEROSIS12:30 - 12:40
TRATMENT A 143
THE SUSTAINED DISEASE ACTIVITY FREE STATUS AS
MEASURE OF THERAPEUTIC RESPONSE & THE LONG TERM
IMPACT OF IMMUNOMODULATORY TREATMENT
12:40 - 12:50
Committee: Amilton
Barreira, Patricio Abad
e Alina Quevedo
Secretary: Giselle
Lourenço
A 146TREATMENT FAILURE IN MULTIPLE SCLEROSIS:
VECTRIMS CRITERIA12:50 - 13:00
A 116
REACTIVATION OF DISEASE ACTIVITY IN PATIENTS
WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB
DISCONTINUATION: A CASE REPORT IN VENEZUELA.
13:00 - 13:10
A 134
THE CERVICAL SPINAL CORD IN NEUROMYELITIS
OPTICA PATIENTS: A COMPARATIVE STUDY WITH
MULTIPLE SCLEROSIS USING DIFFUSION TENSOR
IMAGING
13:10 - 13:20
A 144TRACT BASED SPATIAL STATISTICS (TBSS) IN THE
EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.13:20 - 13:30
A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40
THE ABSTRACTS OF THE 7TH CONGRESS OF LACTRIMS-RIO 2012 ARE
PUBLISHED IN MULTIPLE SCLEROSIS JOURNAL, 2012. 18 (55)
76 77
78 79
BETAFERON® - BETAINTERFERONA 1B - REG. MS – 1.0020.0080INDICAÇÕES - PACIENTES COM UM ÚNICO EVENTO CLÍNICO SUGESTIVO DE ESCLEROSE MÚLTIPLA (SÍNDROME CLINICAMENTE ISOLADA) - PARA RETARDAR A PROGRESSÃO À ESCLEROSE MÚLTIPLA DEFINIDA. ESCLEROSE MÚLTIPLA RECORRENTE-REMITENTE (EMRR). ESCLEROSE MÚLTIPLA SECUNDÁRIA PROGRESSIVA (EMSP). CONTRAINDICAÇÕES: BETAFERON® (BETAINTERFERONA 1B) É CONTRAINDICADO EM PACIENTES COM HISTÓRIA DE HIPERSENSIBILIDADE À BETAINTERFERONA NATURAL OU RECOMBINANTE OU A QUALQUER EXCIPIENTE DO PRODUTO. CUIDADOS E ADVERTÊNCIAS: A ADMINISTRAÇÃO DE CITOCINAS AOS PACIENTES COM GAMOPATIA MONOCLONAL PRÉ-EXISTENTE FOI ASSOCIADA COM O DESENVOLVIMENTO DE SÍNDROME DE EXTRAVASAMENTO CAPILAR SISTÊMICO, COM SINTOMAS QUE SE ASSEMELHAM AO CHOQUE E EVOLUÇÃO FATAL. PACIENTES QUE VENHAM A SER TRATADOS COM BETAFERON® (BETAINTERFERONA 1B) DEVEM SER INFORMADOS QUE PODEM OCORRER DISTÚRBIOS DEPRESSIVOS E IDÉIAS SUICIDAS COMO EFEITOS SECUNDÁRIOS DO TRATAMENTO, DEVENDO COMUNICAR IMEDIATAMENTE AO MÉDICO A OCORRÊNCIA DESTES SINTOMAS. O MEDICAMENTO DEVE SER ADMI-NISTRADO COM CUIDADO AOS PACIENTES COM HISTÓRIA OU DIAGNÓSTICO DE DISTÚRBIOS DEPRESSIVOS OU COM IDÉIAS SUICIDAS. ESTE PRODUTO CONTÉM ALBUMINA HUMANA E, PORTANTO, EXISTE UM RISCO EXTREMAMENTE REMOTO PARA A TRANSMISSÃO DE DOENÇAS VIRAIS. O RISCO TEÓRICO PARA A TRANSMISSÃO DA DOENÇA DE CREUTZFELD-JACOB É CONSIDERADO TAMBÉM EXTREMAMENTE REMOTO. ALÉM DOS TESTES DE LABORATÓRIO REQUERIDOS NORMALMENTE PARA O MONITORAMENTO DE PACIENTES COM ESCLEROSE MÚLTIPLA, É RECOMENDADA A REALIZAÇÃO DOS SEGUINTES TESTES, ANTES DO INÍCIO E NO PERÍODO APÓS A INTRODUÇÃO DO TRATAMENTO EM INTERVALOS REGULARES, E DEPOIS PERIODICAMENTE NA AUSÊNCIA DE SINTOMAS CLÍNICOS: HEMOGRAMA COMPLETO E LEUCOGRAMA DIFERENCIAL, CONTAGEM DE PLAQUETAS E BIOQUÍMICA DO SANGUE INCLUINDO TESTES DE FUNÇÃO HEPÁTICA ( TGO, TGP E �GT). SÃO RECOMENDADOS TESTES PERIÓDICOS DA FUNÇÃO TIREOIDIANA NOS PACIENTES COM HISTÓRIA DE DISFUNÇÃO DA TIRÓIDE OU COM INDICAÇÃO CLÍNICA. BETAFERON® (BETAINTERFERONA 1B) DEVE SER ADMINISTRADO COM CAUTELA EM PACIENTES COM HISTÓRIA DE CONVULSÕES. DEVE SER UTILIZADO COM CUIDADO EM PACIENTES COM DISTÚRBIOS CARDÍACOS PRÉ-EXISTENTES. MULHERES EM IDADE FÉRTIL DEVEM ADOTAR MEDIDAS CONTRACEPTIVAS APROPRIADAS. NÃO É CONHECIDO SE BETAFERON® (BETAINTERFERONA 1B) PODE CAUSAR LESÃO FETAL QUANDO ADMINISTRADO ÀS MULHERES GRÁVIDAS OU SE PODE AFETAR A CAPACIDADE REPRODUTIVA HUMANA. DEVIDO À OCORRÊNCIA POTENCIAL DE REAÇÕES ADVERSAS GRAVES NOS LACTENTES, DEVE-SE DECIDIR ENTRE A INTERRUPÇÃO DA AMAMENTAÇÃO OU DO TRATAMENTO COM BETAFERON® (BETAINTER-FERONA 1B). EM PACIENTES SUSCETÍVEIS, OS EFEITOS ADVERSOS RELACIONADOS AO SNC ASSOCIADOS COM O USO DE BETAFERON® (BETAINTERFERONA 1B) PODEM INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS. INTERAÇÃO MEDICAMENTOSA: NÃO FORAM REALIZADOS ESTUDOS SISTEM-ATIZADOS DE INTERAÇÃO DE BETAFERON® (BETAINTERFERONA 1B) COM OUTROS MEDICAMENTOS. FOI RELATADO QUE AS INTERFERONAS REDUZEM A ATIVIDADE DE ENZIMAS HEPÁTICAS DEPENDENTES DO CITOCROMO P450 EM SERES HUMANOS E NOS ANIMAIS. DEVE-SE TER CAUTELA QUANDO BETAFERON® (BETAINTERFERONA 1B) É ADMINISTRADO EM COMBINAÇÃO COM MEDICAMENTOS QUE APRESENTAM ESTREITA MARGEM TERAPÊUTICA E SÃO LARGAMENTE DEPENDENTES DO SISTEMA HEPÁTICO CITOCROMO P450 PARA A SUA DEPURAÇÃO. DEVE-SE TER CUIDADO NA ADMINISTRAÇÃO CONCOMITANTE DE MEDICAMENTOS QUE TENHAM EFEITO SOBRE O SISTEMA HEMATOPOIÉTICO. REAÇÕES ADVERSAS: FREQÜENTEMENTE FORAM OBSERVADOS SINTOMAS SEMELHANTES AOS GRIPAIS (FEBRE, CALAFRIOS, ARTRALGIA, INDISPOSIÇÃO GERAL, SUDORESE, CEFALÉIA OU MIALGIA). A OCORRÊNCIA DESTES SINTOMAS DIMINUIU COM O PASSAR DO TEMPO. DE MODO GERAL, RECOMENDA-SE A TITULAÇÃO DA DOSE NO INÍCIO DO TRATAMENTO, A FIM DE AUMENTAR A TOLERABILIDADE AO BETAFERON® (BETAINTERFERONA 1B) (VER ITEM “POSOLOGIA”). SINTOMAS SEMELHANTES AOS GRIPAIS TAMBÉM PODEM SER REDUZIDOS COM A ADMINISTRAÇÃO DE UM ANTIINFLAMATÓRIO NÃO ESTEROIDAL. REAÇÕES NO LOCAL DE INJEÇÃO OCORRERAM FREQÜENTEMENTE APÓS A ADMINISTRAÇÃO DE BETAFERON® (BETAINTERFERONA 1B). VERMELHIDÃO, INCHAÇO, ALTERAÇÃO DE COR, INFLAMAÇÃO, DOR, HIPERSENSIBILIDADE, NECROSE E REAÇÕES NÃO-ESPECÍFICAS FORAM ASSOCIADAS, DE MODO SIGNIFICATIVO, AO TRATAMENTO COM 0,25 MG (8 MILHÕES DE UI) DE BETAFERON® (BETAINTERFERONA 1B). A NECROSE PODE SER EXTENSA E PODE ENVOLVER A FÁSCIA MUSCULAR, ASSIM COMO TECIDO ADIPOSO E, PORTANTO, PODE RESULTAR EM FORMAÇÃO DE CICATRIZ. OCASIONALMENTE SÃO NECESSÁRIOS DEBRIDAMENTO E, MENOS FREQÜENTEMENTE, ENXERTO DE PELE. DE MODO GERAL, A INCIDÊNCIA DE REAÇÕES NO LOCAL DE INJEÇÃO DIMINUIU COM O PASSAR DO TEMPO. O TRATAMENTO COM BETAFERON® PODE ASSOCIAR-SE COM ALTER-AÇÕES HEMATOLÓGICAS (ANEMIA, LEUCOPENIA E TROMBOCITOPENIA) E ALTERAÇÕES HEPATOBILIARES (ALTERAÇÕES DAS ENZIMAS ALANINA AMINOTRANSFERASE E ASPARTATO AMINOTRANSFERASE). ASSIM COMO PARA OUTRAS BETAINTERFERONAS, FORAM RELATADOS CASOS RAROS DE LESÃO HEPÁTICA GRAVE, INCLUINDO FALÊNCIA HEPÁTICA, EM PACIENTES TRATADOS COM BETAFERON® (BETAINTERFERONA 1B). OS EVENTOS MAIS GRAVES FREQÜENTEMENTE OCORRERAM EM PACIENTES QUE UTILIZAVAM OUTROS FÁRMACOS OU SUBSTÂNCIAS HEPATOTÓXICAS OU NA PRESENÇA DE CONDIÇÕES MÉDICAS GRAVES CONCOMITANTES (POR EXEMPLO: DOENÇA MALIGNA COM METÁSTASE, INFECÇÃO GRAVE E SEPTICEMIA, ABUSO DE BEBIDAS ALCOÓLICAS). RARAMENTE O TRATAMENTO COM BETAFERON® FOI ASSOCIADO À DISFUNÇÃO DA TIREÓIDE (HIPO OU HIPERTIROIDISMO); ANOREXIA E CONVULSÃO. ALOPECIA, PRURIDO, URTICÁRIA, MIALGIAS OCORRERAM POUCO FREQUENTEMENTE DURANTE O TRATAMENTO COM BETAFERON®. RARAMENTE OBSERVARAM-SE ALTERAÇÕES MENSTRUAIS E PANCREATITE AGUDA POR HIPERTRIGLICERIDEMIA. POSOLOGIA: O TRATAMENTO COM BETAFERON® (BETAINTERFERONA 1B) DEVE SER INICIADO COM A SUPERVISÃO DE UM MÉDICO EXPERIENTE NO TRATAMENTO DA ESCLEROSE MÚLTIPLA. A DOSE RECOMENDADA DE BETAFERON® (BETAINTERFERONA 1B) É DE 0,25 MG (8 MILHÕES DE UI), CONTIDA EM 1 ML DA SOLUÇÃO RECONSTITUÍDA (VER, EM ANEXO, INSTRUÇÕES DETALHADAS PARA PREPARAÇÃO E ADMINISTRAÇÃO), DEVENDO SER INJETADA POR VIA SUBCUTÂNEA, EM DIAS ALTERNADOS. GERALMENTE, A TITULAÇÃO DA DOSE É RECOMENDADA NO INÍCIO DO TRATAMENTO. OS PACIENTES DEVEM INICIAR O TRATAMENTO COM 0,0625 MG (0,25 ML), POR VIA SUBCUTÂNEA, EM DIAS ALTERNADOS, E AUMENTAR A DOSE GRADUALMENTE PARA 0,25 MG (1,0 ML), EM DIAS ALTERNADOS. O PERÍODO DE TITULAÇÃO PODE SER AJUSTADO DE ACORDO COM A TOLERABILIDADE INDIVIDUAL. VENDA SOB PRESCRIÇÃO MÉDICA.
VENDAS SOB PRESCRIÇÃO MÉDICA. BETAFERON NÃO DEVE SER USADO EM PACIENTES CARDIOPATAS. BETAFERON PODE APRESENTAR INTERAÇÃO MEDICAMENTOSA COM BEBIDAS ALCÓOLICAS. BETAFERON PODE INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS.
Material destinado exclusivamente à classe médica.Para mais informações consulte a bula do produto ou a BAYER S.A -
produtos farmacêuticos. Rua Domingos Jorge, 1100 - São Paulo - SP - CEP: 04779-900
www.bayerpharma.com.br
L.BR.SM.2012-11-19.0365
Anuncio Betaferon_210x297.indd 1 11/21/12 4:19 PM
80
SPONSORS
GOLD
SILVER
BRONZE